

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

Page numbers followed by *f* and *t* indicate figures and tables respectively.

- Abortions, breast cancer and, 416
- Acetaldehyde, carcinogenesis of, 202
- Acetaminophen, 21, 587
- N*-Acetyltransferase
 - bladder cancer and, 578–579, 590
 - colorectal cancer and, 281–282
 - esophageal cancer and, 205
 - kidney cancer and, 602
 - oral cancer and, 160
 - stomach cancer and, 249–250
- Achalasia, esophageal cancer and, 224
- Acid inhibition therapy, stomach cancer and, 265
- Acne, testicular cancer and, 561
- Acquired immune deficiency syndrome (AIDS)
 - Hodgkin's lymphoma and, 664
 - non-Hodgkin's lymphoma and, 681
- Acrylonitrile, occupational exposure to, 7
- Acute lymphocytic leukemia (ALL), 695, 699–700, 700f. *See also* Leukemias
- Acute myeloid leukemia (AML), 8–9, 13, 695, 700. *See also* Leukemias
- Adenocarcinoma
 - of bladder, 573
 - of breast. *See* Breast cancer
 - of cervix, 446–447
 - human papilloma virus and, 456, 458
 - obesity and, 452
 - oral contraceptives and, 451–452
 - screening programs and, 449
 - colorectal. *See* Colorectal cancer
 - of endometrium. *See* Endometrial cancer
 - of esophagus. *See also* Esophageal cancer
 - body mass index and, 222
 - diet and, 220–221
 - incidence of, 196, 198–201
 - inherited susceptibility, 201
 - somatic mutations, 212–213
 - tobacco/alcohol use and, 214f, 215–216
 - of lung
 - carcinogenesis of, 356f
 - histologic type distribution, 349, 352
 - human papilloma virus infection and, 363
 - somatic mutations and, 355–356, 356t
 - tobacco use and, 358
 - of pancreas. *See* Pancreatic cancer
 - of prostate. *See* Prostate cancer
 - of stomach. *See* Stomach cancer
- Adenocarcinoma in situ, of cervix, 447
- Adenoma-carcinoma hypothesis of colorectal cancer, 277–279
- Adenomatous polyps, 275, 277, 281. *See also* Familial adenomatous polyposis
- Adenosquamous cancers of uterus, 468–469
- ADH. *See* Alcohol dehydrogenase
- ADH1B/C* genes, oral cancer and, 160–161
- ADH2/3* genes, esophageal cancer and, 202
- Aflatoxin exposure
 - biomarkers of, 112, 113t
 - hepatitis B virus synergism with, 120
 - liver cancer and, 112, 113t, 120, 314–315, 325
- African Americans
 - lung cancer in, 358
 - testicular cancer in, 559
- Africans, skin cancer in, 379
- Age
 - at first birth, and breast cancer, 416, 431, 435
 - Hodgkin's lymphoma incidence and, 66f, 655–656, 655–656f
 - radiation-associated thyroid cancer and, 646, 646t
- Age-standardized incidence rates, 36–37, 38–39t
- Agricultural workers
 - brain cancer in, 627
 - Hodgkin's lymphoma and, 662–663
 - non-Hodgkin's lymphoma and, 680
 - prostate cancer and, 540
 - stomach cancer and, 263
- AIDS (acquired immune deficiency syndrome)
 - Hodgkin's lymphoma and, 664
 - non-Hodgkin's lymphoma and, 681
- Air pollution, lung cancer and, 366–367, 367t
- Alcohol consumption
 - bladder cancer and, 584
 - brain cancer and, 624
 - breast cancer and, 19, 414–415
 - colorectal cancer and, 19, 291
 - endometrial cancer and, 476
 - esophageal cancer and, 19, 202, 213–216
 - Hodgkin's lymphoma and, 659
 - kidney cancer and, 604–605
 - laryngeal cancer and, 368
 - leukemias and, 702
 - liver cancer and, 19, 316
 - lung cancer and, 361
 - nasopharyngeal carcinoma and, 184
 - non-Hodgkin's lymphoma and, 676–677
 - oropharyngeal cancer and, 18–19, 165–167, 166f
 - ovarian cancer and, 502
 - pancreatic cancer and, 338
 - prostate cancer and, 531
 - as risk factor, 18–19
 - skin cancer and, 387
 - stomach cancer and, 254
 - testicular cancer and, 560
 - thyroid cancer and, 644
- Alcohol dehydrogenase (ADH)
 - esophageal cancer and, 202
 - oral cancer and, 160–161
- Alcohol metabolism, 160, 167, 202
- Aldehyde dehydrogenase (ALDH), esophageal cancer and, 202
- ALDH2* gene, esophageal cancer and, 202
- ALL. *See* Acute lymphocytic leukemia
- Allele, definition of, 102
- Allele-sharing methods
 - definition of, 102
 - gene identification by, 93–94
- Allergies
 - brain cancer and, 628
 - non-Hodgkin's lymphoma and, 683
 - pancreatic cancer and, 343

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- 5-Alpha reductase, prostate cancer and, 533–534
- Alpha-tocopherol. *See* Vitamin E
- AML. *See* Acute myeloid leukemia
- Amphetamines, kidney cancer and, 610
- Analgesics
 - bladder cancer and, 587–588
 - kidney cancer and, 610
 - as risk factor, 21
- Analytic studies, 132
- Androgen receptors
 - endometrial cancer and, 473
 - ovarian cancer and, 498
 - prostate cancer and, 523–524
- Androgens. *See also specific androgens*
 - breast cancer and, 418–420, 419f
 - prostate cancer and, 532–533
- Angiogenesis, cancer progression and, 79–80, 80f
- Angiosarcoma of liver (ASL), 308, 313t
 - arsenic and, 323
 - Thorotrast and, 6–7, 322
 - vinyl chloride and, 10–11, 322–323
- Anthropometric measures
 - bladder cancer and, 584
 - brain cancer and, 624
 - breast cancer and, 427–429
 - cervical cancer and, 452
 - colorectal cancer and, 291–292
 - endometrial cancer and, 482–483
 - esophageal cancer and, 221–222
 - Hodgkin's lymphoma and, 659–660
 - kidney cancer and, 605–607, 606f
 - leukemias and, 702
 - liver cancer and, 317
 - lung cancer and, 362
 - nasopharyngeal carcinoma and, 184
 - non-Hodgkin's lymphoma and, 677
 - oropharyngeal cancer and, 167
 - ovarian cancer and, 507–508
 - pancreatic cancer and, 339–340
 - prostate cancer and, 535–536
 - skin cancer and, 388
 - testicular cancer and, 561–562
 - thyroid cancer and, 645
- Antiandrogenic agents, testicular cancer and, 566
- Antihypertensive medications, kidney cancer and, 609–610
- Antioxidants
 - skin cancer and, 386–387
 - stomach cancer and, 255, 257
- Antiretroviral therapy, non-Hodgkin's lymphoma and, 681
- α 1-Antitrypsin deficiency, liver cancer and, 311
- APC gene, colorectal cancer and, 279–280
- Apoptosis
 - in carcinogenesis, 74–76, 75f
 - definition of, 102
 - p53 protein and, 71–72
- Areca catechu*. *See* Betel nut
- ARF gene, melanoma and, 384–385
- Aromatase inhibitors, breast cancer and, 427
- Aromatic amines, bladder cancer and, 586
- Arsenic
 - basal cell carcinoma and, 389
 - bladder cancer and, 12, 588, 589
 - environmental exposure to, 12
 - kidney cancer and, 604
 - liver cancer and, 323
 - occupational exposure to, 7–8
- Artificial sweeteners
 - bladder cancer and, 584
 - kidney cancer and, 604
- Artificial ultraviolet radiation, skin cancer and, 394
- Asbestos
 - environmental exposure to, 12–13
 - lung cancer and, 8, 365, 367
 - occupational exposure to, 8
 - ovarian cancer and, 509
 - pleural mesothelioma and, 8, 370
 - stomach cancer and, 263
- Asbestosis, 8
- Ascorbic acid. *See* Vitamin C
- ASL. *See* Angiosarcoma of liver
- Aspirin
 - bladder cancer and, 587–588
 - breast cancer and, 431
 - colorectal cancer and, 294, 295f
 - lung cancer and, 366
 - as risk factor, 21
 - stomach cancer and, 260
- Association studies, 96–99, 138–139
- Astrocytoma, 619t, 620, 624, 629
- Ataxia-telangiectasia
 - breast cancer and, 406–407
 - genetic mutations in, 70
 - leukemias and, 699
 - thyroid cancer and, 641
- Atomic bomb survivors
 - bladder cancer and, 584–585
 - brain cancer in, 624–625
 - breast cancer and, 430
 - colon cancer and, 293
 - leukemias and, 694, 704, 705f, 709
 - liver cancer and, 322
 - ovarian cancer and, 508
 - skin cancer and, 389
 - stomach cancer and, 262–263
 - thyroid cancer and, 645–646, 646t
- Australia antigen, 15
- Autoimmune diseases
 - Hodgkin's lymphoma and, 663–664
 - non-Hodgkin's lymphoma and, 682
- Baldness, testicular cancer and, 561
- Barbiturates, bladder cancer and, 588
- Barrett's esophagus, 201, 212–213, 224–225
- Basal cell carcinoma (BCC)
 - alcohol consumption and, 387
 - anthropometric measures and, 388
 - diet and, 386
 - incidence, 379–380
 - infections and, 388
 - inherited susceptibility, 380–382
 - ionizing radiation and, 389

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Basal cell carcinoma (BCC) (*cont.*)
 medical conditions/treatment and, 389
 somatic mutations, 384
 tobacco use and, 385–386
 ultraviolet radiation and, 391–392
- BCC. *See* Basal cell carcinoma
- B-cell neoplasia, 669–670, 671t. *See also* Non-Hodgkin's lymphoma
- Bcl-2 protein, in carcinogenesis, 76
- Benign tumors, vs. malignant tumors, 62, 62t
- Benzene exposure, 8–9, 13, 708
- Beryllium, lung cancer and, 365
- Beta-carotene. *See* Carotenoids
- Betel nut (*Areca catechu*)
 nasopharyngeal carcinoma and, 187
 oral cancer and, 162, 163
- Bethesda System for classification of cervical abnormalities, 447
- Bias
 biomarker-based studies and, 116–117
 publication bias, 121–123, 121f, 122f, 122t
 as systematic error, 142–143
- Bidi, lung cancer and, 358
- Biliary cirrhosis, liver cancer and, 323
- Biliary tract cancer
 clinical synopsis, 308–309
 epidemiology, 324
 pathogenesis mechanisms, 325
 risk factors, 324–325
- Biomarker-based studies
 bias in, 116–117
 confounding in, 117, 119, 119f
 of factor interactions, 119–120, 120t
 limitations of, 110–111
 publication bias and, 121–123, 121f, 122f, 122t
 random error in, 120–121
 transitional studies, 118–119, 118t
 variation in, 117–118, 117t
- Biomarkers, 109–123. *See also* Biomarker-based studies; *names of specific biomarkers*
 defined, 110
 of disease, 109–111, 110f, 112t, 115–116
 epidemiologic applications of, 109–111, 111f, 123
 of exposure, 109–110, 110f, 111–114, 112t, 113t
 intermediate biomarkers, 111, 112t, 114–115
 of susceptibility, 111, 112t, 116
 validation of, 118–119, 118t
- Birth cohort
 breast cancer and, 427
 lung cancer and, 350
 testicular cancer and, 557–558, 558f
 thyroid cancer and, 645
- Birth head circumference, brain cancer and, 624
- Birth order
 brain cancer and, 624
 breast cancer and, 432
 Hodgkin's lymphoma and, 664, 665
 testicular cancer and, 565–566
- Birth weight
 breast cancer and, 23, 432
 childhood leukemias and, 702
 testicular cancer and, 564–565
- Birt-Hogg-Dube syndrome, kidney cancer and, 601
- Bladder cancer, 573–591
 carcinogen metabolism and, 578–579
 diagnosis, 574
 epidemiology
 descriptive, 574–575, 575–577f
 genetic and molecular, 575–580, 577f, 578f
 histologic subgroups, 573
 incidence, 574–575, 575–577f
 inherited susceptibility, 575–580
 nontransitional cell carcinoma, 573, 589–590
 prognosis, 574
 risk factors
 alcohol consumption, 584
 anthropometric measures, 584
 diet, 582–584
 drinking water contamination, 12, 588–589
 infections, 584
 ionizing radiation, 584–585
 medical conditions and treatment, 21, 587–588
 occupational exposure, 9, 585–587, 585t
 overview, 590–591
 physical activity, 584
 reproductive factors and hormones, 584
 slow acetylation polymorphism, 120–121, 121f
 tobacco use, 578–579, 578f, 580–582, 581t, 590
 voiding frequency and urine pH, 589
 somatic mutations, 580
 staging, 573
 symptoms, 574
 treatment, 574
- Blood transfusion, non-Hodgkin's lymphoma and, 681–682
- Bloom's syndrome
 genetic mutations in, 70–71
 leukemias and, 699
- BMI. *See* Body mass index
- Body fat distribution, breast cancer and, 428–429
- Body mass index (BMI)
 breast cancer and, 23, 427–428
 colorectal cancer and, 291–292
 endometrial cancer and, 483
 esophageal cancer and, 221–222
 kidney cancer and, 605, 606f
 liver cancer and, 317
 lung cancer and, 362
 non-Hodgkin's lymphoma and, 677
 prostate cancer and, 535–536
 testicular cancer and, 562
 thyroid cancer and, 645
- Body weight. *See* Body mass index; Obesity; Weight change
- Bone marrow transplantation, leukemias and, 709
- Borrelia burgdorferi*, non-Hodgkin's lymphoma and, 679
- BRAF* proto-oncogene
 melanoma and, 383, 385
 ovarian cancer and, 499
 thyroid cancer and, 642

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Brain cancer, 617–630
 in children, 617, 629–630
 diagnosis, 618
 epidemiology
 descriptive, 618–622, 619t, 620–622f
 genetic and molecular, 622
 histologic subgroups, 618, 619t
 incidence, 618–620, 619t, 620–621f
 inherited susceptibility, 622
 prognosis, 618
 risk factors
 alcohol consumption, 624
 anthropometric measures, 624
 cellular telephones, 629
 diet, 623–624, 629
 drinking water contamination, 623–624, 629
 electromagnetic fields, 629
 head trauma, 628–629
 hormones, 624, 628
 infections, 624
 ionizing radiation, 624–625, 629
 medical conditions and treatment, 628
 occupational exposure, 625–628
 overview, 630
 reproductive factors, 624
 tobacco use, 622–623
 symptoms, 618
 treatment, 618
- BRCA1* gene
 breast cancer and, 91–92, 405–406
 ovarian cancer and, 497
- BRCA2* gene
 breast cancer and, 92, 406
 melanoma and, 384
 ovarian cancer and, 497
- Breast
 benign disease of, breast cancer and, 432–433
 cellular differentiation of, 415–416
 density of, 433
 parenchymal patterns of, 433
- Breast cancer, 403–436
 brain cancer and, 628
 diagnostic methods, 404
 early onset, linkage and, 90–92
 epidemiology
 descriptive, 404–405, 405f, 406f
 genetic and molecular, 405–408
 etiologic model of, 435–436
 familial aggregation of, 90–92
 future research challenges, 436
 histologic subgroups, 403
 incidence, 56f, 57, 404–405, 405f, 406f
 inherited susceptibility, 90–92, 405–408
 in men, 434
 prognosis, 404
 risk factors, 424t
 alcohol consumption, 19, 414–415
 anthropometric measures, 23, 427–429
 breast disease, benign, 432–433
 diet, 22, 23, 408–414
 electromagnetic fields, 434
 environmental pollution, 434
- Breast cancer (*cont.*)
 hormonal chemoprevention, 426–427
 hormone replacement therapy, 20–21, 423–426, 424t
 hormones, endogenous, 417–421
 in utero and perinatal exposures, 432
 infections, 429
 ionizing radiation, 5–6, 430
 mammographic density, 433
 medical conditions and treatment, 431–432
 occupational exposure, 430–431
 oral contraceptives, 20, 421–422
 physical activity, 429–430
 reproductive factors, 17–18, 415–417
 tobacco use, 408
 symptoms, 403
 thyroid cancer and, 648
 treatment, 404
- Breast-feeding
 breast cancer and, 17, 416
 Hodgkin's lymphoma and, 659
 ovarian cancer and, 504
- Breast-ovarian cancer syndrome, 497
- British Doctors Study, 134
- Bronchitis, chronic, lung cancer and, 366
- Burkitt's lymphoma, 677, 678
- Butter consumption, esophageal cancer and, 219
- E-cadherin, stomach cancer and, 246, 252, 253
- Cadmium exposure, prostate cancer and, 539–540
- Calcium
 colorectal cancer and, 290
 prostate cancer and, 528
- Campylobacter jejuni* infection, non-Hodgkin's lymphoma and, 679
- Cancer. *See also specific cancer sites and names of specific cancers*
 clinical behavior of, 66
 definition of, 62–64, 62t
 grading and staging of, 66
 metastasis of, 63–64
 mortality from, vs. other causes of death, 44–45, 45t
 mortality trends in United States, 48–49, 49–50f
 origins of. *See* Carcinogenesis
 overall survival rate, 57–58, 58t
 progression of, 62–63, 78–81, 80f
 unlimited replicative potential of, 65, 76–78, 77f
- Cancer burden
 geographic variability by site, 49–51, 51–56f, 57, 59
 mortality by cause, 47–48, 48t
 by site, 45–47, 46–47f
- Cancer genes. *See also* DNA repair genes; Gene identification strategies; Proto-oncogenes; Tumor-suppressor genes
 in carcinogenesis, 66–67
 categories of, 66
 examples of, 90–92, 91t
 mechanisms of gene disruption and, 87–88
- Cancer stem cells, 65
- Carbohydrate intake, pancreatic cancer and, 337–338

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Carbonated soft drinks, esophageal cancer and, 221
- Carcinogen exposure, biomarkers of, DNA adducts as, 114
- Carcinogen metabolism
 - detoxification and, 68
 - esophageal cancer and, 203–205
 - gene–gene and gene–environment interactions, 99
 - oral cancer and, 159, 160
 - in tobacco-related bladder carcinogenesis, 578–579, 578f
- Carcinogenesis
 - apoptosis and, 74–76, 75f
 - cancer genes and, 66–67
 - cell cycle and checkpoints and, 69–70, 69f
 - cellular mechanisms, 64–65, 64f
 - epigenetic gene silencing and, 68–69
 - exogenous mutagenesis and, 68
 - genetic mechanisms of, 62–63, 67–68, 67f
 - genomic instability disorders and, 70–71
 - growth-regulatory signaling pathways and, 72–74, 73f
 - IARC classification, 147, 148t
 - multistep theory of, 68
 - p53 pathways and, 71–72, 72f
 - retinoblastoma pathways and, 71, 72, 73f
 - tobacco-related, 578–579, 578f
- Carcinogens. *See also names of specific carcinogens*
 - exogenous, in carcinogenesis, 68
 - occupational exposure to, 7–11
- Carcinoma. *See also names of specific carcinomas, e.g., Adenocarcinoma*
 - of bladder. *See* Bladder cancer
 - nasopharyngeal. *See* Nasopharyngeal carcinoma
 - or thyroid gland. *See* Thyroid cancer
- Carcinoma in situ
 - of breast, 403
 - of cervix, 15–16, 447, 457, 457f
 - defined, 63
- Cardia cancer. *See* Stomach cancer
- Carney's syndrome, thyroid cancer and, 641
- β -carotene. *See* Carotenoids
- Carotenoids
 - breast cancer and, 411–412
 - cervical cancer and, 451
 - lung cancer and, 360, 360t
 - oral cancer and, 164–165
 - pancreatic cancer and, 337
 - skin cancer and, 387
 - stomach cancer and, 256–257
- Case–control studies, 97–98, 135–138, 137f
- Case-only design, 98–99
- Caspases, 75
- Causal pie model, 128, 128f, 129ft
- Causation. *See also* Etiology
 - inference of, 127–129, 146–149, 147t, 148t
 - public health standards and, 146
- Cause, definition of, 127, 150
- CCND1* gene, esophageal cancer and, 209, 211
- CDH1* gene, stomach cancer and, 246, 252, 253
- CDK4* gene, melanoma and, 383
- CDKN2A* gene
 - esophageal cancer and, 211, 212
 - melanoma and, 383
- CDKN2A/ARF* locus, melanoma and, 384–385
- Celiac disease
 - esophageal cancer and, 224
 - non-Hodgkin's lymphoma and, 682
- Cell cycle, 69–70, 69f
- Cell senescence, 76–78
- Cellular origins of cancer, 64–65, 64f
- Cellular telephones, brain cancer and, 629
- Cervical abnormalities, classification systems for, 447
- Cervical cancer, 446–462. *See also under*
 - Adenocarcinoma
 - carcinoma in situ, 15–16, 447, 457, 457f
 - diagnosis, 447
 - epidemiology
 - descriptive, 447–449, 448f
 - genetic and molecular, 449–450
 - future challenges, 461
 - histologic subgroups, 446–447
 - human papilloma virus vaccination and, 460
 - incidence, 447–449, 448f
 - inherited susceptibility, 449
 - prognosis, 447
 - risk factors
 - anthropometric measures, 452
 - diet, 450–451
 - hormones, 20, 451–452
 - infections, 15–16, 452–460, 454f, 457f, 458f, 461
 - ionizing radiation, 460
 - medical conditions, 461
 - occupational exposure, 461
 - physical activity, 460
 - reproductive factors, 451
 - sexual behavior, 452
 - tobacco use, 450
 - screening for, 449, 459
 - somatic mutations, 449–450
 - symptoms, 447
 - treatment, 447
 - Cervical intraepithelial neoplasia (CIN), 15, 447
 - Checkpoints, cell cycle, 69–70, 69f
 - CHEK2* gene, breast cancer and, 407
 - Chemical dyes
 - bladder cancer and, 586
 - occupational exposure to, 9
 - Chemotherapy
 - leukemias and, 709
 - lung cancer and, 366
 - Chernobyl nuclear accident, 636, 646–647
 - Chewing tobacco
 - bladder cancer and, 582
 - esophageal cancer and, 214, 215
 - oral cancer and, 162, 163
 - pancreatic cancer and, 337
 - Childbearing. *See* Parity
 - Childhood diet, breast cancer and, 23
 - Childhood infections, leukemia and, 703–704
 - Childhood obesity, breast cancer and, 428–429

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Children
 brain cancer in, 617, 629–630
 Hodgkin's lymphoma in, 656, 661, 665
 leukemias in, 694, 695, 696, 702, 703–704
 non-Hodgkin's lymphoma in, 670, 677, 681
 radiation-associated thyroid cancer and, 646–647, 646t
- Chili pepper, stomach cancer and, 257
- China, nasopharyngeal carcinoma risk in, 177–179, 179f
- Chlamydia infection, prostate cancer and, 537
- Chlamydia pneumoniae* infection, lung cancer and, 362
- Chlamydia trachomatis* infection, cervical cancer and, 452–453
- Chlorinated hydrocarbon solvents
 cervical cancer and, 461
 kidney cancer and, 608
 liver cancer and, 323
 non-Hodgkin's lymphoma and, 680
 pancreatic cancer and, 340
- Chlorination by-products
 bladder cancer and, 588–589
 brain cancer and, 629
 kidney cancer and, 604
- Cholangiocarcinoma, 308, 313t, 325
 hepatitis virus infections and, 318, 320
 ionizing radiation and, 322
 liver flukes and, 322, 325
 primary sclerosing cholangitis and, 323
- Cholangitis, sclerosing
 liver cancer and, 323
 pancreatic cancer and, 343
- Cholecystectomy
 colorectal cancer and, 293–294
 pancreatic cancer and, 341
- Cholecystokinin, pancreatic cancer and, 339
- Cholelithiasis, biliary tract cancer and, 324, 325
- Cholesterol, serum levels of, testicular cancer and, 560
- Chromium
 environmental exposure to, 13–14
 lung cancer and, 365
 occupational exposure to, 9–10
- Chromosomal alterations, as biomarkers for cancer
 risk, 114–115, 115t
- Chromosome 8q24, prostate cancer risk and, 523
- Chromosome, definition of, 102
- Chronic lymphocytic leukemia (CLL), 695, 700–701.
 See also Leukemias; Non-Hodgkin's lymphoma
- Chronic myeloid leukemia (CML), 65, 695, 701. *See also* Leukemias
- Chuttha cancer, 163
- Cigar smoking
 bladder cancer and, 582
 kidney cancer and, 602
 lung cancer and, 358
 oral cancer and, 163
- Cigarette smoking. *See* Tobacco use
- Cigarettes, tar content of, lung cancer and, 357–358
- CIN (cervical intraepithelial neoplasia), 15, 447
- Cirrhosis
 hepatitis C virus infection and, 320
 hepatocellular carcinoma and, 312, 316, 323, 325
- Clamidia psittaci* infection, non-Hodgkin's lymphoma and, 679
- Clear-cell carcinoma, of uterus, 469
- CLL. *See* Chronic lymphocytic leukemia
- Clonorchis sinensis*, 322
- Clornaphazine, bladder cancer and, 588
- Closed cohorts, 135, 150
- Clustering of leukemia cases, 703
- CML. *See* Chronic myeloid leukemia
- Cockayne syndrome, 382
- Codon, 102
- Coffee consumption
 bladder cancer and, 583
 colorectal cancer and, 290
 kidney cancer and, 604
 lung cancer and, 359
 ovarian cancer and, 500–501
 pancreatic cancer and, 338
 stomach cancer and, 255
 thyroid cancer and, 644
- Cohort studies, 98, 134–135, 136f
- Colorectal cancer, 275–297. *See also* Hereditary nonpolyposis colorectal cancer
 adenoma-carcinoma hypothesis of, 277–279
 diagnosis, 276
 epidemiology
 descriptive, 276–277, 277–279f
 genetic and molecular, 277–284, 280f
 histologic subgroups, 275
 incidence, 276–277, 277–279f
 age-standardized, 50–51, 52f
 inherited susceptibility, 279–284
 mechanisms linked to risk factors, 296t
 nonsteroidal anti-inflammatory drugs and, 21, 283–284, 294–295, 295f
 preventability of, 275, 296–297, 296t
 prognosis, 276
 risk factors
 alcohol consumption, 19, 291
 anthropometric measures, 291–292
 diet, 22, 285–291
 hormones, 291, 292, 295–296
 infections, 292–293
 ionizing radiation, 293
 medical conditions and treatment, 293–295
 NSAID use, 21
 occupational exposure, 293
 physical activity, 292
 reproductive factors, 291
 tobacco use, 284–285
 sequence of genetic mutation in, 277, 280f
 symptoms, 275–276
 treatment, 276
- Colorectal cancer syndrome, inherited, 281
- Common-disease/common-variant hypothesis, 95
- Competing risks, 144, 150
- Component cause, 129, 150
- COMPT* gene, endometrial cancer and, 472
- Confidence intervals, 140, 150

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Confounding
 biomarker-based studies and, 117, 119, 119f
 definition of, 150
 as systematic error, 141–142, 142f, 143f
 tobacco use and, 358
- Congenital immunodeficiency, 17, 664
- Contraceptives. *See also* Oral contraceptives
 progestin-only, breast cancer and, 422
- Cooking methods
 bladder cancer and, 582
 esophageal cancer and, 220
 stomach cancer and, 259
- Cooks, oral cancer in, 168–169
- Corrected survival rate, 42–43
- Cotton dust, nasopharyngeal carcinoma and, 187
- COX-2 (cyclooxygenase-2) inhibitors, colorectal cancer and, 294–295, 295f
- COX-2 gene
 esophageal cancer and, 210, 213
 stomach cancer and, 250
- COXs. *See* Cyclooxygenases
- Crowden's disease, 406, 641
- Cruciferous vegetables
 bladder cancer and, 582
 colorectal cancer and, 285
 kidney cancer and, 603
 lung cancer and, 119–120, 120t, 361
 thyroid cancer and, 643–644
- Cryptorchidism, testicular cancer and, 563, 566
- Cumulative incidence
 as measurement of disease burden, 35t, 37, 40–41t
 in open cohort studies, 135
- Cured-meat consumption, brain cancer and, 623, 629
- Cyclin D1 polymorphisms, esophageal cancer and, 209, 211
- Cyclin/cyclin-dependent kinase complexes, 69
- Cyclophosphamide, bladder cancer and, 588
- Cyclooxygenase-2 (COX-2) inhibitors, colorectal cancer and, 294–295, 295f
- Cyclooxygenases (COXs)
 esophageal cancer and, 210, 213
 liver cancer and, 312–313
 stomach cancer and, 250
- CYP genes. *See* Cytochrome P450 genes
- Cystic fibrosis, pancreatic cancer and, 343
- Cystic kidney disease, acquired, kidney cancer and, 608
- Cystitis, bladder cancer and, 584
- Cytochrome P450 genes
 CYP1A1
 endometrial cancer and, 472
 esophageal cancer and, 202–203
 nasopharyngeal carcinoma and, 182
 oral cancer and, 160
 stomach cancer and, 248
 CYP1A2
 bladder cancer and, 579
 colorectal cancer and, 281–282
 nasopharyngeal carcinoma and, 181
 testicular cancer and, 559
 CYP1B1, endometrial cancer and, 472
 CYP2A6, nasopharyngeal carcinoma and, 181
- Cytochrome P450 genes (*cont.*)
 CYP2E1
 esophageal cancer and, 203–204
 liver cancer and, 312
 nasopharyngeal carcinoma and, 181(2)
 oral cancer and, 160
 stomach cancer and, 248–249
 CYP3A, esophageal cancer and, 204
 CYP17, endometrial cancer and, 471–472
 CYP19, endometrial cancer and, 472
 lung cancer and, publication bias in studies of, 122–123
- Cytokines. *See also names of specific cytokines*
 stomach cancer and, 246–247
- Dairy products
 non-Hodgkin's lymphoma and, 676
 ovarian cancer and, 500
 prostate cancer and, 527, 528
 skin cancer and, 386
 testicular cancer and, 560
- DALY. *See* Disability-adjusted life years
- Databases, polymorphism, 95–96, 96t
- dbSNP database, 96
- DDT (dichlorodiphenyltrichloroethane), 434
- Death, causes of, compared to cancer deaths, 44–45, 45t
- Death receptor pathway, 75–76, 75f
- Dehydroepiandrosterone (DHEA), breast cancer and, 418
- Dental x-rays, brain cancer and, 625
- Deoxyribonucleic acid. *See* DNA
- DES. *See* Diethylstilbestrol
- Descriptive studies, 131
- DHEA (dehydroepiandrosterone), breast cancer and, 418
- Diabetes mellitus
 brain cancer and, 628
 breast cancer and, 431
 colorectal cancer and, 293
 endometrial cancer and, 484
 kidney cancer and, 609
 liver cancer and, 323
 non-Hodgkin's lymphoma and, 684
 pancreatic cancer and, 340–341
- Diagnostic radiation
 brain cancer and, 625
 breast cancer and, 430
 leukemias and, 708
 ovarian cancer and, 509
 thyroid cancer and, 647
- Dichlorodiphenyltrichloroethane (DDT), breast cancer and, 434
- Diesel exhaust
 bladder cancer and, 586
 liver cancer and, 366
 stomach cancer and, 264
- Diet. *See also names of specific dietary constituents*, *e.g.*, Fiber, dietary
 biliary tract cancer and, 324
 bladder cancer and, 582–584
 brain cancer and, 623–624, 629

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Diet (*cont.*)
breast cancer and, 22, 23, 408–414
cervical cancer and, 450–451
childhood, breast cancer and, 23
colorectal cancer and, 22, 285–91
endometrial cancer and, 475–476
esophageal cancer and, 216–221
Hodgkin's lymphoma and, 659
kidney cancer and, 603–604
laryngeal cancer and, 368
leukemias and, 701–702
liver cancer and, 314–316, 325
lung cancer and, 359–361
nasopharyngeal carcinoma and, 183–184
non-Hodgkin's lymphoma and, 676
oropharyngeal cancer and, 164–165
ovarian cancer and, 499–501
pancreatic cancer and, 337–338
prostate cancer and, 526–531, 531t
as risk factor, 21–23
skin cancer and, 386–387
stomach cancer and, 255–260, 266
testicular cancer and, 560
thyroid cancer and, 643–644
Diet pills, kidney cancer and, 610
Dietary supplements, endometrial cancer and, 475
Diethylstilbesterol (DES)
breast cancer and, 432
testicular cancer and, 565
vaginal adenocarcinoma risk and, 19–20
Dihydrotestosterone, prostate cancer and, 532–533
Disability-adjusted life years (DALY), as
measurement of disease burden, 35t, 44
Disease biomarkers, 109–111, 110f, 112t, 115–116.
See also Biomarker-based studies;
Biomarkers
Disease burden
of cancer
geographic variability by site, 49–51, 51–56f,
57, 59
mortality by cause, 47–48, 48t
by site, 45–47, 46–47f
measures of, 34–44
age-standardized incidence, 36–37, 38–39t
cumulative incidence, 35t, 37, 40–41t
disability-adjusted life years, 35t, 44
incidence, 34–36, 35t
life-years lost, 35t, 44
mortality, 35t, 43–44
prevalence, 35t, 37, 38–41t, 42
survival, 35t, 42–43
Disease causation. *See* Causation
Disease risk, polygenic models of, gene–environment
interaction and, 99–100
Diuretic medication, kidney cancer and, 609–610
DNA adducts
as biomarkers for cancer risk, 115
carcinogens and, 114
DNA chip technology, 102
DNA, description of, 102
DNA expression arrays, for large-scale population
studies, 114
DNA methylation. *See* Methylation status
DNA repair, 102
DNA repair genes
bladder cancer and, 579–580
colorectal cancer and, 281
description of, 66
endometrial cancer and, 470–471
esophageal cancer and, 207–208
genomic instability disorders and, 70
lung cancer and, 355
skin cancer and, 382–383
stomach cancer and, 251
Dominant allele, 102
Down's syndrome, leukemias and, 699
Drinking water contamination
arsenic exposure and. *See* Arsenic
bladder cancer and, 12, 588–589
brain cancer and, 623–624, 629
chlorination by-products, 588–589, 604, 629
kidney cancer and, 604
lung cancer and, 367
non-Hodgkin's lymphoma and, 676
Drugs. *See names of specific drugs*
Dust exposure
esophageal cancer and, 223
lung cancer and, 365
nasopharyngeal carcinoma and, 186–187
stomach cancer and, 263
Dye industry, bladder cancer and, 573, 586
Dyes
bladder cancer and, 586–587
non-Hodgkin's lymphoma and, 685
occupational exposure to, 9
Dysgenetic gonads, ovarian cancer and, 497
EBV. *See* Epstein-Barr virus
E-cadherin, stomach cancer and, 246, 252, 253
Ecologic studies, 131–132, 150
EGf. *See* Epidermal growth factor
EGFR. *See* Epidermal growth factor receptor
Egg consumption, ovarian cancer and, 501
Electrical workers, brain cancer in, 626–627
Electromagnetic fields
brain cancer and, 629
breast cancer and, 434
extreme low-frequency, 706, 707–708
leukemias and, 706, 707–708
ELF-EMF (extreme low-frequency electric and
magnetic fields), 706, 707–708
Emphysema, lung cancer and, 366
Endocrine disruptor hypothesis, 566
Endocrine disruptors, 434
Endometrial cancer, 468–486
diagnosis, 469
epidemiology
descriptive, 469–470
genetic and molecular, 470–474, 474t
studies, 468–469
histologic subgroups, 468–469
hormone metabolizing genes and, 471–473
incidence, 469–470, 470f, 471f
inherited susceptibility, 470–471, 474t

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Endometrial cancer (*cont.*)
 prognosis, 469
 risk factors, 485t
 alcohol consumption, 476
 anthropometric measures, 482–483
 diet, 475–476
 hormones, 20, 477–482, 479t, 480f, 481t, 482t, 484
 hypertension, 484
 infections, 483
 ionizing radiation, 483
 medical conditions and treatments, 484
 occupational exposure, 484
 physical activity, 483
 reproductive factors, 18, 476–477
 tamoxifen, 484–485
 tobacco use, 474–475
 xenoestrogens, environmental, 484
 somatic mutations, 473
 steroid receptors and, 473–474
 symptoms, 469
 treatment, 469
- Energy intake
 kidney cancer and, 604
 stomach cancer and, 259
- Engine exhaust
 bladder cancer and, 586
 stomach cancer and, 264
- Environment–gene interaction. *See* Gene–environment interaction
- Environmental exposure, as risk factor, 11–14
- Environmental pollution. *See also* Drinking water contamination
 breast cancer and, 434
 endometrial cancer and, 484
 lung cancer and, 366–367, 367t
 oral cancer and, 159
 passive smoke exposure, 14, 183, 338, 582, 701
 pleural mesothelioma and, 370
- Enzyme, 102. *See also* names of specific enzymes
- EPHX1* gene
 esophageal cancer and, 204
 liver cancer and, 312
- Epidemiologic studies. *See also* Biomarker-based studies
 analysis methods
 effect measures, 143–144
 interaction, 144–145, 145t
 meta-analysis, 145–146
 cancer risks determined by, 3–24
 alcohol consumption, 18–19
 cigarette smoking, 4–5
 diet, 21–23
 environmental exposure, 11–14
 future research directions, 23–24
 iatrogenic exposure, 19–20
 ionizing radiation, 5–7
 microorganisms, 14–17
 occupational exposure, 7–11
 reproductive factors, 17–18
 design of. *See* Study design
 future research promise, 718–719
- Epidemiologic studies (*cont.*)
 genetic, 96–100
 case–control studies, 97–98
 case-only design, 98–99
 cohort studies, 98
 family-based association studies, 98
 future risks and potential of, 101–102
 gene–environment interaction and, 99–101
 genotyping methods used in, 100–101
 study design and, 138–139
 inference of causation and, 127–129, 146–149, 147t, 148t
 interventional, 129–130
 limitations and challenges of, 149–150
 observational, 130–131, 140, 151
 statistical analysis tools for, 139–140
 systematic errors in, 140–143, 142f, 143f
- Epidemiology
 definition of, 150
 scope of, 127
- Epidermal growth factor (EGF)
 esophageal cancer and, 213
 stomach cancer and, 251
- Epidermal growth factor receptor (EGFR)
 carcinogenesis and, 74
 esophageal cancer and, 212, 213
 oral cancer and, 161
- Epigenetic alterations, 102, 116, 182
- Epigenetic gene silencing, in carcinogenesis, 68–69
- Epilepsy, brain cancer and, 628
- Epoxide hydrolase (EPHX)
 esophageal cancer and, 204
 liver cancer and, 312
- Epstein-Barr virus (EBV)
 breast cancer and, 429
 Hodgkin's lymphoma and, 660–662, 660f, 661f, 663
 induction of, by herbal medicines, 187
 nasopharyngeal carcinoma and, 180, 184–186
 non-Hodgkin's lymphoma and, 677–678
 testicular cancer and, 562
- ErB-2 receptor/*ErB-2* gene, in carcinogenesis, 73–74
- Esophageal cancer, 196–225
 diagnosis, 196
 epidemiology
 descriptive, 197–201, 197–200f
 genetic and molecular, 201–213
 histologic subgroups, 196
 inherited susceptibility, 201–210
 polymorphisms, 202–210
 prognosis, 197
 risk factors
 alcohol consumption, 19, 202, 213–216
 anthropometric measures, 221–222
 diet, 216–221
 infections, 222–223
 medical conditions, 223–225
 occupational exposure, 223
 reproductive factors, 221
 socioeconomic status, 225
 tobacco use, 202–203, 213–216
 somatic mutations, 210–213

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Esophageal cancer (*cont.*)
 symptoms, 196
 treatment, 196–197
- Esophogastric junction, cancer of. *See* Stomach cancer
- ESR1* gene, endometrial cancer and, 473
- ESR2* gene, endometrial cancer and, 473
- Estrogen hypothesis of testicular cancer, 565
- Estrogen plus progestin use, breast cancer and, 425–426
- Estrogen receptors
 breast cancer and, 418
 endometrial cancer and, 473
- Estrogenic agents, testicular cancer and, 566
- Estrogens
 breast cancer and, 417–418, 423
 endometrial cancer and, 477–482, 479t, 480f, 481t, 482t
 exogenous. *See* Hormone replacement therapy; Oral contraceptives
 in utero levels of, and breast cancer, 432
 kidney cancer and, 605
 liver cancer and, 316
 lung cancer and, 362
 metabolism of
 breast cancer and, 418, 419f
 endometrial cancer and, 472–473, 474t
 pancreatic cancer and, 339
 prostate cancer and, 534
 thyroid cancer and, 644
- Ethanol metabolism, 160, 167, 202. *See also* Alcohol consumption
- Etiology. *See also* Causation
 causality and, 127–129, 128f, 129f
 interventional epidemiology and, 129–130
 observational epidemiology and, 130–131
- Exercise. *See* Physical activity
- Exogenous hormones. *See* Hormone replacement therapy; Oral contraceptives
- Exogenous mutagenesis, in carcinogenesis, 68
- Exon, 102
- Experimental studies, 130–131, 140–141, 150. *See also* Epidemiologic studies
- Experimental study design. *See* Study design
- Exposure, biomarkers of, 109–110, 110f, 111–114, 112t, 113t
- Extracellular matrix, cancer progression and, 78
- Extravasation, in metastasis, 63
- Extreme low-frequency electric and magnetic fields (ELF-EMF), 706, 707–708
- Extrinsic factors in cancer progression, 78–81
- Familial adenomatous polyposis
 colorectal cancer and, 279–280
 thyroid cancer and, 641
- Familial aggregation
 biliary tract cancer and, 324
 bladder cancer, 575–580
 brain cancer and, 621
 breast cancer, 90–92, 405–408
 cancer gene examples, 90–92, 91t
 cervical cancer and, 449–450
 colorectal cancer and, 279–281
- Familial aggregation (*cont.*)
 endometrial cancer and, 471, 472, 474t
 esophageal cancer and, 201–202
 Hodgkin's lymphoma and, 658–659
 kidney cancer and, 600–602
 leukemias and, 699
 liver cancer and, 311–312
 lung cancer and, 353–355, 354t
 nasopharyngeal carcinoma and, 179–182
 non-Hodgkin's lymphoma and, 674–675
 oropharyngeal cancer and, 159–161
 ovarian cancer and, 496–497
 pancreatic cancer and, 336
 potential causes of, 88–89
 prostate cancer, 521–523
 research methods for identification of, 89–90, 93–94
 skin cancer and, 380–384
 stomach cancer and, 245–246
 testicular cancer and, 559
 thyroid cancer and, 640–641
- Familial diffuse gastric cancer (FDGC), 246
- Familial gastric cancer (FGC), 246
- Familial intestinal gastric cancer (FIGC), 246
- Familial medullary thyroid cancer, 641, 648
- Family-based association studies, 98
- Fanconi's anemia, 71, 699
- Farmers. *See* Agricultural workers
- Fas ligands, in carcinogenesis, 76
- Fat, dietary
 breast cancer and, 408–411, 410f
 colorectal cancer and, 289–290
 endometrial cancer and, 475–476
 esophageal cancer and, 220–221
 lung cancer and, 359–360
 non-Hodgkin's lymphoma and, 676
 oral cancer and, 165
 ovarian cancer and, 500, 501
 pancreatic cancer and, 338
 prostate cancer and, 527
 skin cancer and, 386
 stomach cancer and, 259
 testicular cancer and, 560
- Fat distribution, in body. *See* Body mass index; Obesity
- Fatty acids, dietary, prostate cancer and, 527–528
- Fatty liver disease, nonalcoholic, liver cancer and, 323
- FDGC (familial diffuse gastric cancer), 246
- Females. *See* Women
- Ferguson-Smith syndrome, skin cancer and, 383–384
- Fertility
 breast cancer and, 431
 ovarian cancer and, 503
 testicular cancer and, 561
- Fertility drugs, ovarian cancer and, 503
- FGC (familial gastric cancer), 246
- FGFR2* gene, breast cancer and, 407–408
- FHIT* gene, esophageal cancer and, 212
- Fiber, dietary
 breast cancer and, 411
 colorectal cancer and, 286–287
 endometrial cancer and, 475–476

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Fiber, dietary (*cont.*)
 - oral cancer and, 165
 - pancreatic cancer and, 337
 - as risk factor, 22
 - stomach cancer and, 257
- Fibroblast growth factor receptor 2, breast cancer and, 407–408
- FIGC (familial intestinal gastric cancer), 246
- Fish consumption, prostate cancer and, 528
- Fish, salt-preserved, nasopharyngeal carcinoma and, 183–184
- Fluid intake, bladder cancer and, 583–584
- Folate (folic acid)
 - breast cancer and, 412–413
 - cervical cancer and, 451
 - colorectal cancer and, 282–283, 283f, 287
 - pancreatic cancer and, 338
 - stomach cancer and, 250–251
- Follow-up, loss to, 42, 144, 150
- Food. *See also* Diet
 - cooking methods
 - bladder cancer and, 582
 - esophageal cancer and, 220
 - stomach cancer and, 259
 - cured, brain cancer and, 623, 629
 - hot
 - esophageal cancer and, 217, 220
 - laryngeal cancer and, 368
 - oropharyngeal cancer and, 169
 - pickled
 - esophageal cancer and, 219
 - stomach cancer and, 259–260
 - salt-preserved, nasopharyngeal carcinoma and, 183–184
- Formaldehyde
 - nasopharyngeal carcinoma and, 186
 - occupational exposure to, 10
- Fragile histidine triad gene, esophageal cancer and, 212
- Frameshift maturation, 102
- Fruit consumption
 - bladder cancer and, 582–583
 - brain cancer and, 623
 - breast cancer and, 413–414
 - cervical cancer and, 451
 - colorectal cancer and, 285–288
 - esophageal cancer and, 216, 218, 220, 221
 - kidney cancer and, 603
 - laryngeal cancer and, 368
 - lung cancer and, 359
 - nasopharyngeal carcinoma and, 184
 - oral cancer and, 164
 - ovarian cancer and, 501
 - pancreatic cancer and, 337
 - stomach cancer and, 255
- Fumarate Hydratase* mutations, kidney cancer and, 601
- Galactose intake, ovarian cancer and, 500
- Gallbladder cancer. *See* Biliary tract cancer
- Gallbladder disease
 - biliary tract cancer and, 324
 - pancreatic cancer and, 341
- Gallstones, biliary tract cancer and, 324, 325
- Gardner's syndrome
 - colorectal cancer and, 279
 - thyroid cancer and, 641
- Gastrectomy, partial
 - pancreatic cancer and, 342–343
 - stomach cancer and, 264–265
- Gastric cancer. *See* Stomach cancer
- Gastric cardia, cancer of, 239, 244–245
- Gastric ulcer, stomach cancer and, 264
- Gastrin, pancreatic cancer and, 339
- Gastroesophageal reflux, esophageal cancer and, 224
- Gastrointestinal hormones, pancreatic cancer and, 339
- Gene amplification, 102
- Gene–environment interaction
 - biomarker-based studies and, 119–120, 120t
 - oral cancer and, 159
 - polygenic models of disease risk and, 99–100
 - susceptibility biomarkers and, 116
- Gene–gene interaction, biomarker-based studies and, 119
- Gene identification strategies, 88–94
 - allele-sharing methods, 93–94
 - alternative methods, 93
 - for common, low-risk disease alleles, 94–95
 - genotyping methods, 100–101
 - limitations of segregation and linkage analysis, 92–93
 - linkage analysis, 89–90
 - examples of, 90–92, 91t
 - limitations of, 92–93
 - positional cloning, 90
 - segregation analysis, 89, 92–93
- Gene silencing, epigenetic, in carcinogenesis, 68–69
- General population cohorts, 134
- Genes. *See also* Cancer genes; Gene identification strategies; *names of specific genes*
 - definition of, 102
 - disruption mechanisms, 87–88
 - mutations. *See* Mutations
 - polymorphisms. *See* Polymorphisms
- Genetic association. *See* Association studies
- Genetic changes, carcinogenesis and, 62–63, 67–68, 67f
- Genetic epidemiologic studies. *See* Epidemiologic studies, genetic
- Genetic factors
 - endometrial cancer and, 470–473
 - ovarian cancer and, 496–498
- Genetic linkage. *See* Linkage analysis
- Genetic mutations. *See* Mutations
- Genetic variation, cancer susceptibility and, 87
- Genome, definition of, 102
- Genome, human, variation in, 87, 94–95, 116
- Genome-wide scans, 101, 116
- Genomic imprinting, 102–103
- Genomic instability disorders, carcinogenesis and, 70–71
- Genotype, 103, 116

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Genotyping, 100–101, 103
Geographic variability by site, 49–51, 51–56f, 57, 59
Germline, definition of, 103
Germline mutations
 ovarian cancer and, 497
 vs. somatic mutations, 87
 stomach cancer and, 245–252
Gestational duration, testicular cancer and, 565
Glioma. *See* Brain cancer
Glucose intolerance, endometrial cancer and, 484
Glutathione *S*-transferase (GST)
 bladder cancer and, 579, 590
 esophageal cancer and, 204–205
 gene–environment interaction and, 99
 liver cancer and, 312
 nasopharyngeal carcinoma and, 181
 oropharyngeal cancer and, 159–160
 ovarian cancer and, 498
 stomach cancer and, 249
Goiter, endemic, 643, 648
Gonads, dysgenetic, ovarian cancer and, 497
Gonorrhea, prostate cancer and, 537
Gorlin's syndrome, skin cancer and, 380–382
Grading of tumors, 66
Green tea, esophageal cancer and, 220
Growth factors
 esophageal cancer and, 212, 213
 liver cancer and, 312–313
 proangiogenic, in carcinogenesis, 78
 stomach cancer and, 251–252
Growth hormone treatment, leukemias and, 702
Growth-regulatory signaling pathways, in
 carcinogenesis, 72–74, 73f
GST. *See* Glutathione *S*-transferase
GSTM1 gene
 bladder cancer and, 579, 590
 esophageal cancer and, 204
 gene–environment interaction and, 99
 liver cancer and, 312
 oropharyngeal cancer and, 159–160
 ovarian cancer and, 498
 stomach cancer and, 249
GSTP1 gene
 esophageal cancer and, 205
 oropharyngeal cancer and, 160
 ovarian cancer and, 498
GSTT1 gene
 esophageal cancer and, 204–205
 liver cancer and, 312
 oropharyngeal cancer and, 160
 ovarian cancer and, 498
 stomach cancer and, 249
Hair dyes
 bladder cancer and, 586–587
 non-Hodgkin's lymphoma and, 685
HapMap Project, 96
HBsAg. *See* Hepatitis B surface antigen
HBV. *See* Hepatitis B virus infection
HCC (hepatocellular carcinoma). *See* Liver cancer
HCV. *See* Hepatitis C virus infection
HDGC (hereditary diffuse gastric cancer), 245–246
Head trauma, brain cancer and, 628–629
Health professionals, brain cancer in, 627
Heavy metals. *See* Metals
Height
 breast cancer and, 23, 427
 Hodgkin's lymphoma and, 659–660
 kidney cancer and, 607
 leukemias and, 696, 702
 lung cancer and, 362
 prostate cancer and, 536
 testicular cancer and, 561
 thyroid cancer and, 645
Helicobacter pylori infection
 colorectal cancer and, 292–293
 esophageal cancer and, 222–223
 non-Hodgkin's lymphoma and, 679
 stomach cancer and, 16–17, 260–262, 261f, 265–266
Hemochromatosis
 esophageal cancer and, 224
 liver cancer and, 311
Hepatic cancer. *See* Liver cancer
Hepatitis A virus infection (HVA), 14–15
Hepatitis B surface antigen (HBsAg), 314, 315, 317–319
Hepatitis B virus infection (HBV)
 aflatoxin exposure synergism, 120
 chronic, global distribution of, 317–318
 hepatitis C infection interaction, 318, 321
 liver cancer and, 14–15, 317–319
Hepatitis, chronic, 320
Hepatitis C virus infection (HCV)
 hepatitis B infection interaction, 318, 321
 hepatocellular carcinoma and, 14–15
 liver cancer and, 319–322
 non-Hodgkin's lymphoma and, 678–679
Hepatocellular carcinoma (HCC). *See* Liver cancer
Herbal medicines, nasopharyngeal carcinoma and, 187
Hereditary diffuse gastric cancer (HDGC), 245–246
Hereditary nonpolyposis colorectal cancer (HNPCC)
 colorectal cancer and, 280–281
 endometrial cancer and, 470–471
 gene mutation identification, 93
 ovarian cancer and, 497
 stomach cancer and, 246
Hereditary pancreatitis, pancreatic cancer and, 342
Hereditary papillary renal cell carcinoma, 601
Herpes simplex virus infection (HSV)
 cervical cancer and, 452
 oral cancer and, 168
 prostate cancer and, 537
Heterocyclic amines, esophageal cancer and, 220
Heterozygosity, 103. *See also* Loss of heterozygosity
HHV8. *See* Human herpes virus 8
High blood pressure
 endometrial cancer and, 484
 kidney cancer and, 609–610
High blood pressure, kidney cancer and, 609–610
Hill criteria for inferring causation, 146, 147t
Hispanics, skin cancer in, 379
Histogenesis, 66
HIV. *See* Human immunodeficiency virus

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- HLA* complex genes
 cervical cancer and, 449
 nasopharyngeal carcinoma and, 180–181
 stomach cancer and, 248
- hMLH1* gene, stomach cancer and, 253
- HNPCC. *See* Hereditary nonpolyposis colorectal cancer
- Hodgkin's lymphoma, 653–665
 diagnosis, 654
 epidemiology
 descriptive, 654–658, 654–658f
 genetic and molecular, 658–659
 histologic subgroups, 653
 incidence, 654–658, 654–658f
 inherited susceptibility, 658–659
 prognosis, 654
 risk factors
 alcohol consumption, 659
 anthropometric measures, 659–660
 diet, 659
 infections, 660–662, 660–662f, 664–665
 ionizing radiation, 662
 medical conditions and treatment, 663–664
 occupational exposure, 662–663
 physical activity, 662
 reproductive factors and hormones, 659
 sibship size, 664–665
 socioeconomic status, 664–665
 tobacco use, 659
 symptoms, 653–654
 treatment, 654
 WHO classification of, 671t
 in young adults, 654–658, 658f, 661–662, 665
- Hormonal chemoprevention, breast cancer and, 426–427
- Hormone metabolizing genes. *See also names of specific genes*
 breast cancer and, 418
 endometrial cancer and, 471–473, 474t
 ovarian cancer and, 498
- Hormone receptors
 androgen, 473, 498, 523–524
 estrogen, 418, 473
 progesterone, 362, 473, 498
- Hormone replacement therapy (HRT)
 biliary tract cancer and, 325
 breast cancer and, 20–21, 423–426, 424t
 colorectal cancer and, 295–296
 endometrial cancer and, 478–482, 479t, 480f, 481t, 482t
 lung cancer and, 362
 melanoma and, 388
 ovarian cancer and, 505–506
 as risk factor, 20–21
- Hormones. *See also names of specific hormones*
 biliary tract cancer and, 324–325
 bladder cancer and, 584
 brain cancer and, 624, 628
 breast cancer and, 417–421
 cervical cancer and, 20, 451–452
 colorectal cancer and, 291, 292
- Hormones (*cont.*)
 endometrial cancer and, 20, 477–482, 479t, 480f, 481t, 482t, 484
 esophageal cancer and, 221
 exogenous. *See* Hormone replacement therapy;
 Oral contraceptives
 Hodgkin's lymphoma and, 659
 kidney cancer and, 605
 leukemias and, 702
 liver cancer and, 316–317
 lung cancer and, 362
 nasopharyngeal carcinoma and, 184
 non-Hodgkin's lymphoma and, 677
 ovarian cancer and, 504–507
 pancreatic cancer and, 339
 prostate cancer and, 532–535
 skin cancer and, 387–388
 testicular cancer and, 560–561
 during gestation, 565
 thyroid cancer and, 644–645
- HPV. *See* Human papilloma virus infection
- HRAS1* gene
 breast cancer and, 407
 ovarian cancer and, 498
- HRT. *See* Hormone replacement therapy
- HSD17B* gene family, endometrial cancer and, 472
- HSV. *See* Herpes simplex virus infection
- hTERT* gene, stomach cancer and, 253
- HTLV-1. *See* Human T-cell leukemia/lymphoma virus 1
- Human genome, variation in, 87, 94–95, 116
- Human herpes virus 8 (HHV8), non-Hodgkin's lymphoma and, 678
- Human immunodeficiency virus (HIV)
 and cancer risk, 17
 cervical cancer and, 453, 457
 Hodgkin's lymphoma and, 664
 non-Hodgkin's lymphoma and, 678, 681
- Human leukocyte antigen (HLA)
 cervical cancer and, 449
 nasopharyngeal carcinoma and, 180–181
 stomach cancer and, 248
- Human mammary tumor virus, 429
- Human papilloma virus infection (HPV)
 bladder cancer and, 584
 cervical cancer and, 15–16, 453–460, 461
 cancer prevention, 459–460
 epidemiology, 455–459, 457f, 458f
 vaccination, 460
 virology, 453–454, 454f
 virus detection, 454–455
 endometrial cancer and, 483
 esophageal cancer and, 222
 laryngeal cancer and, 369–370
 lung cancer and, 363
 nasopharyngeal carcinoma and, 186
 oral cancer and, 167–168
 prostate cancer and, 537–538
 skin cancer and, 388
- Human T-cell leukemia/lymphoma virus 1 (HTLV-1)
 leukemias and, 694, 702–703
 non-Hodgkin's lymphoma and, 678

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Human telomerase transcriptase gene, human (hTERT), stomach cancer and, 253
- HVA (hepatitis A virus infection), 14–15
- Hydrocele, testicular cancer and, 564
- 17 β -Hydroxysteroid dehydrogenase, endometrial cancer and, 472
- Hyperinsulinemia, pancreatic cancer and, 341
- Hypermethylation, in epigenetic gene silencing, 68
- Hypernephroma, 597
- Hyperplasia, in carcinogenesis, 63
- Hypertension
- endometrial cancer and, 484
 - kidney cancer and, 609–610
- Hyperthyroidism, thyroid cancer and, 647–648
- Hypospadias, testicular cancer and, 563–564, 566
- Hypothyroidism, thyroid cancer and, 647–648
- Hysterectomy, ovarian cancer and, 503–504
- IARC. *See* International Agency for Research on Cancer
- Iatrogenic exposure, as risk factor, 19–20
- IL-1B* gene, stomach cancer and, 246–247
- Imatinib, 695
- Immune modulation
- leukemia and, 704
 - non-Hodgkin's lymphoma and, 680–681
- Immune response, cervical cancer and, 457
- Immunization. *See* Vaccination
- Immunodeficiency. *See also* Acquired immune deficiency syndrome
- and cancer risk, 17
 - congenital, 17, 664
 - Hodgkin's lymphoma and, 664
 - leukemias and, 699
 - non-Hodgkin's lymphoma and, 675
- Immunosuppression, non-Hodgkin's lymphoma and, 681
- Immunosurveillance evasion, in carcinogenesis, 80–81, 80f
- Immunotherapy, 81
- In utero exposures. *See* Prenatal exposures
- Incidence, cumulative
- as measurement of disease burden, 35t, 37, 40–41t
 - in open cohort studies, 135
- Incidence rates. *See also under names of specific cancer sites*
- age-standardized, 36–37, 38–39t
 - as measurement of disease burden, 34–36, 35t
- Indoor air pollution, lung cancer and, 366
- Infections. *See also names of specific infections*
- bladder cancer and, 584
 - brain cancer and, 624
 - breast cancer and, 429
 - cervical cancer and, 15–16, 452–460, 454f, 457f, 458f, 461
 - childhood, 703–704
 - colorectal cancer and, 292–293
 - endometrial cancer and, 483
 - esophageal cancer and, 222–223
 - Hodgkin's lymphoma and, 660–662, 660–662f, 664–665
 - kidney cancer and, 607, 609
- Infections (*cont.*)
- laryngeal cancer and, 369–370
 - leukemias and, 702–704
 - liver cancer and, 14–15, 317–322, 325
 - lung cancer and, 362–363
 - nasopharyngeal carcinoma and, 184–186
 - non-Hodgkin's lymphoma and, 677–679, 682–683
 - oropharyngeal cancer and, 167–168
 - ovarian cancer and, 508
 - prostate cancer and, 537–539
 - skin cancer and, 388–389
 - stomach cancer and, 16–17, 260–262
 - testicular cancer and, 562
- Infectious causes of cancer, 14–17
- Infectious disease, chronic, non-Hodgkin's lymphoma and, 682–683
- Infectious hepatitis, 14–15
- Infectious mononucleosis
- Hodgkin's lymphoma and, 663
 - nasopharyngeal carcinoma and, 185–186
- Infertility
- breast cancer and, 431
 - ovarian cancer and, 503
 - testicular cancer and, 561
- Inflammatory bowel disease, colorectal cancer and, 293
- Inflammatory conditions
- non-Hodgkin's lymphoma and, 684
 - ovarian cancer and, 509
 - prostate cancer and, 524, 537
- Inflammatory mediators, esophageal cancer and, 209
- Information bias, 117, 142, 150
- Inguinal hernia, testicular cancer and, 564
- Inherited colorectal cancer syndrome, 281
- Inherited susceptibility. *See* Familial aggregation; *under names of specific cancer sites*
- Insulin levels, endometrial cancer and, 484
- Insulin-like growth factor binding proteins, prostate cancer and, 534
- Insulin-like growth factors
- breast cancer and, 420–421
 - leukemias and, 702
 - liver cancer and, 312–313
 - lung cancer and, 362
 - prostate cancer and, 524, 534
- Interaction, 144–145, 145t
- Interleukin-1, stomach cancer and, 246–247
- Intermediate biomarkers, 111, 112t, 114–115
- Intermittent UV exposure theory, 391, 392–393
- International Agency for Research on Cancer (IARC), 147, 148t
- Interventional studies, 129–130
- Intrauterine exposures. *See* Prenatal exposures
- Intravasation, in metastasis, 63
- Intron, 103
- Iodine intake, thyroid cancer and, 643, 648
- Ionizing radiation
- bladder cancer and, 584–585
 - brain cancer and, 624–625, 629
 - breast cancer and, 5–6, 430
 - cervical cancer and, 460
 - colorectal cancer and, 293

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Ionizing radiation (*cont.*)
 endometrial cancer and, 483
 Hodgkin's lymphoma and, 662
 kidney cancer and, 607
 leukemias and, 5, 704–706, 705f, 707
 liver cancer and, 6–7, 322
 lung cancer and, 6, 363
 nasopharyngeal carcinoma and, 186
 non-Hodgkin's lymphoma and, 679
 oropharyngeal cancer and, 168
 ovarian cancer and, 508–509
 pancreatic cancer and, 340
 pleural mesothelioma and, 370
 prostate cancer and, 539
 as risk factor, 5–7
 skin cancer and, 5, 389
 stomach cancer and, 262–263
 testicular cancer and, 562
 thyroid cancer and, 6, 645–647, 645t, 646t, 648–649
- Iron overload, esophageal cancer and, 220
- Isoniazid, bladder cancer and, 588
- Isothiocyanates, 120, 355, 361, 361f, 643
- JC virus, colorectal cancer and, 293
- Kangri cancers, 394
- Kaposi's sarcoma, human immunodeficiency virus and, 17
- Keratinocyte skin cancer. *See* Basal cell carcinoma; Squamous cell carcinoma, of skin
- Kidney cancer, 597–611
 diagnosis, 598
 epidemiology
 descriptive, 598–600, 599–600f, 601t
 genetic and molecular, 600–602, 601t
 histologic subgroups, 597
 incidence, 598–600, 599–600f, 601t
 inherited susceptibility, 600–602
 prognosis, 598
 risk factors
 alcohol consumption, 604–605
 anthropometric measures, 605–607, 606f
 diet, 603–604
 infections, 607, 609
 ionizing radiation, 607
 medical conditions and treatment, 21, 608–610
 occupational exposure, 608
 overview, 610–611, 611t
 physical activity, 607
 reproductive factors and hormones, 605
 socioeconomic status, 610
 tobacco use, 602–603, 603t
 somatic mutations, 602
 symptoms, 597–598
 treatment, 598
- Killer T lymphocytes
 in apoptosis, 75–76
 in immune-mediated tumor eradication, 80–81, 80f
- KRAS* gene
 endometrial cancer and, 473
 lung cancer and, 356–357
 ovarian cancer and, 499
 stomach cancer and, 252
- Lactose intake, ovarian cancer and, 500
- Large bowel cancer. *See* Colorectal cancer
- Large-scale population studies, 114
- Laryngeal cancer, 368–370, 368–370f
- Laxative use, colorectal cancer and, 294
- Lentigo maligna melanoma, 380, 383, 385, 390, 393
- Leukemias, 694–710. *See also names of specific types of leukemia*
 diagnosis, 695
 epidemiology
 descriptive, 696–699, 697–698f
 genetic and molecular, 699–701, 700f
 histologic subgroups, 694–695, 696
 incidence, 696–698, 697f, 698f
 inherited susceptibility, 699
 prognosis and progress, 695–696
 risk factors
 alcohol consumption, 702
 anthropometric measures, 702
 diet, 701–702
 formaldehyde exposure, 10
 hormones, 702
 infections, 702–704
 ionizing radiation, 5, 704–706, 705f, 707
 medical conditions and treatment, 7, 708–709
 occupational exposure, 8–9, 707–708
 perinatal factors, 702
 physical activity, 704
 reproductive factors, 702
 tobacco use, 701
 somatic mutations, 699–701, 700f
 symptoms, 695
 treatment, 695
- Life-years lost, as measurement of disease burden, 35t, 44
- Li-Fraumeni syndrome
 brain cancer and, 621
 breast cancer and, 406
 gene mutation identification in, 93
 leukemias and, 699
 lung cancer and, 353
 skin cancer and, 383, 384
 stomach cancer and, 246
- Linkage, 103
- Linkage analysis
 applications of, 138
 cancer susceptibility genes identified by, 90–92, 91t
 in family pedigree analysis, 89–90
 limitations of, 92–93
- Linkage disequilibrium, 89, 95, 138
- Lipid intake. *See also* Fat, dietary
 lung cancer and, 359
- Liver cancer, 308–323. *See also* Angiosarcoma of liver; Cholangiocarcinoma
 diagnosis, 308–309

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Liver cancer (*cont.*)
epidemiology
 descriptive, 309–311, 309–311f
 molecular epidemiology, 311–313
histologic subgroups, 308
incidence, 309–311, 309–311f
 age-standardized, 51, 53f
inherited susceptibility, 311–312
prognosis, 309
risk factors
 aflatoxin exposure, 112, 113t, 120, 314–315, 325
 alcohol consumption, 19, 316
 anthropometric measures, 317
 diet, 314–316, 325
 hormones, 316–317
 infections, 14–15, 317–322, 325
 ionizing radiation, 6–7, 322
 medical conditions and treatment, 323
 occupational exposure, 322–323
 overview, 313–314, 313t, 325
 reproductive factors, 316
 tobacco use, 314
somatic mutations, 312–313
symptoms, 308
treatment, 309
Liver flukes, liver cancer and, 322, 325
Longitudinal studies, 134–135
Loss of heterozygosity (LOH), 103, 211, 212, 253
Loss to follow-up, 42, 144, 150
Lung cancer, 349–367, 371. *See also under*
 Adenocarcinoma; Small-cell carcinoma;
 Squamous cell carcinoma
diagnosis, 350
epidemiology
 descriptive, 350–353, 351–353f, 353t
 genetic and molecular, 353–357, 354t
family history, 353–355
histologic subgroups, 349–350, 352
incidence, 54f, 57, 350–353, 351–353f, 353t
pathogenesis mechanisms, 355–357, 356f
prevention of, 371
prognosis, 350
risk factors
 air pollution, 366–367, 367t
 alcohol consumption, 361
 anthropometric measures, 362
 CYP2D6 gene, 122–123, 122f
 diet, 359–361
 drinking water contamination, 367
 hormones, 362
 infections, 362–363
 ionizing radiation, 6, 363
 medical conditions and treatment, 366
 occupational exposure, 7–11, 363–366, 364t
 physical activity, 363
 reproductive factors, 362
 tobacco use, 4–5, 357–359
somatic mutations, 355–357, 356t
symptoms, 350
treatment, 350
Lung fibrosis, lung cancer and, 366
Lycopene
 pancreatic cancer and, 337
 prostate cancer and, 528–529
Lymphocytes. *See* Killer T lymphocytes
Lymphocytic leukemias, 695. *See also* Leukemias
Lymphoma. *See* Hodgkin's lymphoma; Non-Hodgkin's lymphoma
Lynch syndrome. *See* Hereditary nonpolyposis colorectal cancer
Magnetic fields. *See* Electromagnetic fields
Males. *See* Men
Malignancy, characteristics of, 62, 62t
Malignant tumors, vs. benign tumors, 62, 62t
Mammographic density, breast cancer and, 433
Matched case–control studies, 138
Maté consumption
 laryngeal cancer and, 368–369
 oropharyngeal cancer and, 169
Maternal age, testicular cancer and, 566
Matrix metalloproteinases, 78–79
MC1R gene, melanoma and, 385
Measures of disease burden. *See* Disease burden, measures of
Meat consumption
 bladder cancer and, 582
 brain cancer and, 623
 colorectal cancer and, 288–289
 esophageal cancer and, 219, 220, 221
 kidney cancer and, 604
 lung cancer and, 359
 non-Hodgkin's lymphoma and, 676
 pancreatic cancer and, 338
 prostate cancer and, 527
 skin cancer and, 386
 stomach cancer and, 258–259
Meat industry/butchers, oral cancer in, 169
Medical conditions. *See names of specific medical conditions*
Medical treatments. *See names of specific medical treatments*
Medications. *See names of specific medications*
mEH gene. *See* Microsomal epoxide hydrolase
Meiosis, 103
Melanocortin-1 receptor gene, melanoma and, 385
Melanoma
 alcohol consumption and, 387
 anthropometric measures and, 388
 diet and, 387
 divergent pathway model of, 393
 hormones and, 388
 incidence, 55f, 57, 380, 380–382f
 infections, 388
 inherited susceptibility, 383–384
 medical conditions/treatment and, 390
 occupational exposure and, 389
 reproductive factors and, 387
 somatic mutations, 384–385
 tobacco use and, 386
 ultraviolet radiation and, 392–393
Melatonin, breast cancer and, 430–431
MEN. *See* Multiple endocrine neoplasia

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Men, cancer incidence in
 age-standardized incidence, 39t, 51–56f
 bladder cancer, 574, 576f, 577f
 brain cancer, 620, 621f, 622f
 breast cancer, 434
 colorectal cancer, 276, 279f
 cumulative incidence, 41t
 esophageal cancer, 197–198, 198f, 200f
 Hodgkin's lymphoma, 654, 655f, 656f, 657f
 kidney cancer, 598, 599f, 600f
 laryngeal cancer, 369f, 370f
 leukemia, 696, 697f, 698f
 liver cancer, 310, 310f, 311f
 lung cancer, 350, 351f, 352f, 358
 melanoma, 380, 381f, 382f
 nasopharyngeal carcinoma, 177, 177f, 178, 179f
 non-Hodgkin's lymphoma, 670, 673f, 674f
 oropharyngeal cancer, 156–158, 157f, 158f
 pancreatic cancer, 334f, 335f, 336, 518–519
 prostate cancer, 519f, 520f, 522f
 by site, 47f
 stomach cancer, 240–241, 242f, 243f
 testicular cancer, 556–559, 556–558f
 thyroid cancer, 637, 639f, 640t, 641f
- Menarche
 breast cancer and, 415
 endometrial cancer and, 476
 liver cancer and, 316
 ovarian cancer and, 507
 thyroid cancer and, 644
- Mendelian inheritance, 103
- Meningioma. *See* Brain cancer
- Menopause
 breast cancer and, 417
 endometrial cancer and, 476
 liver cancer and, 316
 ovarian cancer and, 507
 thyroid cancer and, 644
- Mesothelioma, pleural, 8, 370–371
- Meta-analyses, 145–146
- Metabolism
 of alcohol, 160, 167, 202
 of carcinogens
 detoxification and, 68
 esophageal cancer and, 203–205
 gene–gene and gene–environment interactions, 99
 oral cancer and, 159, 160
 in tobacco-related bladder carcinogenesis, 578–579, 578f
 of ethanol, 160, 167, 202
 of hormones, 418, 471–473, 474t, 498
- Metabolomics, large-scale population studies and, 114
- Metal workers, bladder cancer in, 585, 586
- Metals. *See also names of specific metals*
 lung cancer and, 365
 nasopharyngeal carcinoma and, 187–188
- Metaplasia-dysplasia-carcinoma sequence, 212
- Metastasis, mechanisms of, 63–64
- Metastatic colonization, 64
- Methionine synthase, esophageal cancer and, 206
- Methionine synthase reductase (MTRR), esophageal cancer and, 206
- Methylation status
 esophageal cancer and, 205–207
 stomach cancer and, 252–253
 as susceptibility biomarker, 116
- Methylenetetrahydrofolate reductase (MTHFR)
 colorectal cancer and, 282–283, 283f
 esophageal cancer and, 205–206
 gene–environment interaction and, 99–100
 stomach cancer and, 250–251
- Microarray analysis, for large-scale population studies, 114
- Micronutrients. *See also names of specific micronutrients*
 bladder cancer and, 582
 breast cancer and, 411–413
 colorectal cancer and, 285–286
 esophageal cancer and, 216–218
 liver cancer and, 315
 oral cancer and, 164–165
 stomach cancer and, 259
- Microorganisms, as risk factor, 14–17
- MicroRNAs, epigenetic gene silencing and, 68–69
- Microsatellite instability (MIN), 93, 103, 253
- Microsomal epoxide hydrolase (mEH)
 colorectal cancer and, 282
 esophageal cancer and, 204
 stomach cancer and, 249
- Microsporium canis* infection, lung cancer and, 363
- Milk consumption, ovarian cancer and, 500
- MIN (microsatellite instability), 93, 103, 253
- Miscarriages, breast cancer and, 416
- Missense mutation, 103
- Molecular epidemiology, 123. *See also* Biomarkers; Epidemiologic studies, genetic
- Monoclonal lineage, 64–65, 64f
- Mononucleosis, infectious
 Hodgkin's lymphoma and, 663
 nasopharyngeal carcinoma and, 185–186
- Monounsaturated fats, breast cancer and, 411
- Mortality rates
 from cancer, vs. other causes of death, 44–45, 45t
 by cause, 47–48, 48t
 as measurement of disease burden, 35t, 43–44
 trends in United States, 48–49, 49–50f
- Mouse mammary tumor virus, 429
- Mouthwash, oropharyngeal cancer and, 169
- MTHFR* gene
 colorectal cancer and, 282–283, 283f
 esophageal cancer and, 207
 gene–environment interaction and, 99–100
 stomach cancer and, 250–251
- MTR* gene, esophageal cancer and, 207
- MTRR* gene, esophageal cancer and, 206
- Mucins, stomach cancer and, 248
- Multihit hypothesis of carcinogenesis, 68, 278, 280, 287
- Multiple endocrine neoplasia (MEN), thyroid cancer and, 640, 641, 648
- Multiple hamartoma syndrome, 406, 461
- Multiple sclerosis, brain cancer and, 628

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Multistep theory of carcinogenesis. *See* Multihit hypothesis of carcinogenesis
- Mumps orchitis, testicular cancer and, 562
- Mutagenesis, exogenous, in carcinogenesis, 68
- Mutations. *See also specific mutations*
- accumulation of, in tumors, 65
 - in carcinogenesis, 67–68, 67f, 81
 - definition of, 103
 - germline
 - ovarian cancer and, 497
 - vs. somatic, 87
 - stomach cancer and, 245–252
 - identification of. *See* Gene identification strategies
 - types of, 87–88, 88f
- Mutator phenotype, 62–63
- MutLhomolog 1 colon cancer (hMLH1), stomach cancer and, 253
- c-Myc* gene, in carcinogenesis, 74
- Mycotoxins, esophageal cancer and, 220
- Myeloid leukemias, 7, 695. *See also* Leukemias
- MYH* gene, colorectal cancer and, 281
- NAD(P)H:quinone oxidoreductase1 (NQO1), esophageal cancer and, 205
- NAFLD (nonalcoholic fatty liver disease), 323
- NASH (nonalcoholic steatohepatitis), 323
- NASIDs. *See* Nonsteroidal anti-inflammatory drugs
- Nasopharyngeal carcinoma (NPC), 175–188. *See also* Oral and pharyngeal cancer
- diagnosis, 176
 - epidemiology
 - descriptive, 177–179
 - genetic and molecular, 179–182
 - histologic subgroups, 175
 - incidence, 176–179, 177–181f
 - prognosis, 176–177
 - risk factors
 - alcohol consumption, 184
 - anthropometric measures, 184
 - betel nut, 187
 - diet, 183–184
 - formaldehyde exposure, 10
 - heavy metals, 187–188
 - hormones, 184
 - infections, 184–186
 - ionizing radiation, 186
 - medical conditions and treatment, 187
 - occupational exposure, 186–187
 - physical activity, 186
 - reproductive factors, 184
 - tobacco use, 182–183
 - symptoms, 175–176
 - treatment, 176
- Nasopharynx, anatomy of, 176f
- Nass, oral cancer and, 162, 163
- Naswar, oral cancer and, 162
- NAT1* gene
 - colorectal cancer and, 281–282
 - stomach cancer and, 249–250
- NAT2* gene
 - bladder cancer and, 578–579, 590
 - colorectal cancer and, 281–282
 - NAT2* gene (cont.)
 - esophageal cancer and, 205
 - kidney cancer and, 602
 - oral cancer and, 160
 - stomach cancer and, 249–250
- Natural experiment, 148
- Necessary cause, 128–129, 150–151
- Neonatal jaundice, testicular cancer and, 564
- Nested case–control studies, 136–137
- NF1* gene, melanoma and, 384
- NHL. *See* Non-Hodgkin's lymphoma
- Nickel
 - lung cancer and, 365
 - nasopharyngeal carcinoma and, 188
 - occupational exposure to, 10
- Night-shift work, breast cancer risk and, 430–431
- Nitrates in drinking water
 - brain cancer and, 623–624
 - non-Hodgkin's lymphoma and, 676
- Nitrosamine exposure
 - brain cancer and, 623, 629
 - esophageal cancer and, 219
 - kidney cancer and, 602
 - oral cancer and, 168
 - stomach cancer and, 258
- Nonalcoholic fatty liver disease (NAFLD), liver cancer and, 323
- Nonalcoholic steatohepatitis (NASH), liver cancer and, 323
- Nonexperimental studies. *See* Observational studies
- Non-Hodgkin's lymphoma (NHL), 669–685
- diagnosis, 670
 - epidemiology
 - descriptive, 670–674, 672–675f
 - genetic and molecular, 674–675
 - histologic subgroups, 669–670, 671t, 685
 - trends in, 672–674
 - incidence, 670, 672–675f
 - unexplained increase in, 669, 674, 685
 - inherited susceptibility, 674–675
 - prognosis and progress, 670
 - risk factors
 - alcohol consumption, 676–677
 - anthropometric measures, 677
 - diet, 676
 - hair dyes, 685
 - hormones, 677
 - infections, 677–679
 - ionizing radiation, 679
 - medical conditions and treatment, 17, 680–684
 - occupational exposure, 679–680
 - physical activity, 679
 - reproductive factors, 677
 - tobacco use, 675–676
 - ultraviolet radiation, 684–685
 - symptoms, 670
 - treatment, 670
 - WHO classification of, 669–670, 671t
- Noninterventional studies, 130–131
- Nonseminoma testicular cancer. *See* Testicular cancer
- Nonsense mutation, 103

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Nonsteroidal anti-inflammatory drugs (NSAIDs)
 bladder cancer and, 587–588
 breast cancer and, 431
 colorectal cancer and, 21, 283–284, 294–295, 295f
 lung cancer and, 366
 non-Hodgkin's lymphoma and, 683
 ovarian cancer and, 509
 as risk factor, 21
 stomach cancer and, 260
- Nontransitional cell carcinoma (NTCC), 573, 589–590
- Norplant, breast cancer and, 422
- NPC. *See* Nasopharyngeal carcinoma
- NQO1* gene, esophageal cancer and, 205
- NTCC (nontransitional cell carcinoma), 573, 589–590
- Nuclear industry workers, leukemias in, 707
- Nucleotide, 103
- Nulliparity
 breast cancer and, 415
 cervical cancer and, 451
 colorectal cancer and, 291
 endometrial cancer and, 476
 Hodgkin's lymphoma and, 659
 ovarian cancer and, 502
- Nurses Health Study, 134, 137
- Obesity
 biliary tract cancer and, 324
 bladder cancer and, 584
 brain cancer and, 624
 breast cancer and, 23, 417, 427–428
 cervical cancer and, 452
 colorectal cancer and, 291–292
 endometrial cancer and, 482–483
 kidney cancer and, 605–607
 liver cancer and, 317
 non-Hodgkin's lymphoma and, 677
 ovarian cancer and, 507–508
 pancreatic cancer and, 339–340
 as risk factor, 22–23
- Observational studies, 130–131, 140, 151. *See also*
 Epidemiologic studies
- Observed survival rate, 42
- Occupational exposure
 bladder cancer and, 9, 585–587, 585t
 brain cancer and, 625–628
 breast cancer and, 430–431
 cervical cancer and, 461
 colorectal cancer and, 293
 endometrial cancer and, 484
 esophageal cancer and, 223
 Hodgkin's lymphoma and, 662–663
 kidney cancer and, 608
 laryngeal cancer and, 369
 leukemias and, 707–708
 liver cancer and, 322–323
 lung cancer and, 7–11, 363–366, 364t
 nasopharyngeal carcinoma and, 186–187
 non-Hodgkin's lymphoma and, 679–680
 oropharyngeal cancer and, 168–169
 ovarian cancer and, 509
 pancreatic cancer and, 340
 of parents, leukemias and, 708
- Occupational exposure (*cont.*)
 prostate cancer and, 539–540
 as risk factor, 7–11
 skin cancer and, 389
 stomach cancer and, 263–264
 testicular cancer and, 562–563
 thyroid cancer and, 647
- Odds ratio, 135, 151
- Olive oil consumption, breast cancer and, 410–411
- Oncogenes. *See also names of specific genes*
 cell cycle regulators as, 70
 ovarian cancer and, 498
- Open cohorts, 135, 151
- Opisthorchis felineus*, 322
- Opisthorchis viverrini*, 322
- Oral and pharyngeal cancer. *See also* Nasopharyngeal carcinoma
 diagnosis, 156
 epidemiology
 descriptive, 156–159, 156–158f
 genetic and molecular, 159–161
 histologic subgroups, 155
 incidence, 156–158, 156–158f
 inherited susceptibility, 159–161
 prognosis, 156
 risk factors, 161–169, 162t
 alcohol consumption, 18–19, 165–167, 166f
 anthropometric measures, 167
 diet, 164–165
 infections, 167–168
 ionizing radiation, 168
 maté consumption, 169
 medical conditions and treatment, 169
 mouthwash, 169
 occupational exposure, 168–169
 physical activity, 168
 reproductive factors, 167
 tobacco use, 162–164, 166f
 somatic mutations, 161
 symptoms, 155–156
 treatment, 156
- Oral contraceptives
 biliary tract cancer and, 325
 breast cancer and, 20, 421–422
 cervical cancer and, 20, 451–452
 endometrial cancer and, 477–478
 kidney cancer and, 605
 liver cancer and, 317
 melanoma and, 388
 ovarian cancer and, 504
 as risk factor, 20
 thyroid cancer and, 644, 645
- Orchitis, testicular cancer and, 562
- Organ transplants
 bone marrow, 709
 and cancer risk, 17, 389–390, 680, 681
- Organic solvents
 cervical cancer and, 461
 kidney cancer and, 608
 liver cancer and, 323
 non-Hodgkin's lymphoma and, 680
 pancreatic cancer and, 340

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Organophosphate pesticides, non-Hodgkin's lymphoma and, 680
- Outdoor air pollution, lung cancer and, 366–367, 367t
- Ovarian cancer, 494–511
 - diagnosis, 495
 - epidemiology
 - descriptive, 495–496
 - genetic and molecular, 496–499
 - histologic subgroups, 494–495
 - incidence, 495–496, 495f, 496f
 - inherited susceptibility, 496–498
 - pathogenesis mechanisms, 506t, 507, 510–511
 - prognosis, 495
 - risk factors
 - alcohol consumption, 502
 - anthropometric measures, 507–508
 - diet, 499–501
 - hormones, 20, 504–507
 - infections, 508
 - ionizing radiation, 508–509
 - medical conditions and treatment, 509
 - occupational exposure, 509
 - physical activity, 508
 - reproductive factors, 18, 502–504
 - talcum powder, 509–510
 - tobacco use, 499
 - somatic mutations, 498–499
 - symptoms, 495
 - treatment, 495
- OVCA1/2* genes, ovarian cancer and, 499
- Ovulatory cycles, lifetime number of, ovarian cancer and, 506–507

- p16* gene, oral cancer and, 161
- p53* gene. *See also TP53* gene
 - breast cancer and, 406
 - cervical cancer and, 449, 450
 - esophageal cancer and, 208–209, 210–211, 212
 - lung cancer and, 353
 - oral cancer and, 159, 161, 167
 - ovarian cancer and, 498–499
 - skin cancer and, 384, 385
- p53* protein
 - apoptosis and, 75
 - in carcinogenesis, 71–72, 72f
- p53* tumor pathways, in carcinogenesis, 71–72, 72f
- Paan, oral cancer and, 162, 163
- PAHS (polycyclic aromatic hydrocarbons), 365–366
- Pancreatic cancer, 333–343
 - diagnosis, 334
 - epidemiology
 - descriptive, 334–336, 334–335f
 - genetic and molecular, 336
 - histologic subgroups, 333
 - incidence, 334–335f, 336, 343
 - inherited susceptibility, 336
 - prognosis, 334
 - risk factors
 - alcohol consumption, 338
 - anthropometric measures, 339–340
 - coffee consumption, 338
 - diet, 337–338
- Pancreatic cancer (*cont.*)
 - hormones, 339
 - ionizing radiation, 340
 - medical conditions and treatment, 340–343
 - occupational exposure, 340
 - overview, 343
 - physical activity, 340
 - reproductive factors, 338–339
 - tobacco use, 336–337
 - symptoms, 333
 - treatment, 334
- Pancreatitis, pancreatic cancer and, 342
- Papillomatosis, laryngeal cancer and, 369–370
- Paracetamol (acetaminophen), 21, 587
- Parity
 - biliary tract cancer and, 324–325
 - brain cancer and, 624
 - breast cancer and, 415–416
 - cervical cancer and, 451
 - colorectal cancer and, 291
 - endometrial cancer and, 476–477
 - Hodgkin's lymphoma and, 659
 - liver cancer and, 316
 - ovarian cancer and, 502–503
 - pancreatic cancer and, 339
 - as risk factor, 17–18
 - thyroid cancer and, 644
- Partial gastrectomy
 - pancreatic cancer and, 342–343
 - stomach cancer and, 264–265
- Passive smoking. *See* Smoke, environmental exposure to
- patched* gene, skin cancer and, 382, 384
- Paterson-Kelly syndrome, 223–224
- PCBs. *See* Polychlorinated biphenyls
- PCR (polymerase chain reaction), 100, 103
- Pedigree, 103
- Pedigree analysis, 89–94
- Penetrance
 - cancer risk and, 88–89
 - definition of, 103
 - linkage studies and, 92
- Peptic ulcer, stomach cancer and, 264
- Perinatal factors
 - breast cancer and, 432
 - leukemias and, 702
 - prostate cancer and, 541
 - testicular cancer and, 564–565
- Period analysis of survival, 43
- Pernicious anemia, pancreatic cancer and, 341–342
- Person-time
 - definition of, 151
 - study design and, 132–134, 133f
- Pesticides
 - brain cancer and, 627
 - non-Hodgkin's lymphoma and, 680
- Petrochemical workers, brain cancer in, 626
- Peutz-Jeghers syndrome, ovarian cancer and, 497
- PGR* gene. *See* Progesterone receptors
- Pharyngeal cancer. *See* Nasopharyngeal carcinoma; Oral and pharyngeal cancer

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Phenacetin
 bladder cancer and, 587
 kidney cancer and, 610
 as risk factor, 21
- Phenocopy, 103
- Phenotype, 93, 103, 116
- Physical activity
 bladder cancer and, 584
 breast cancer and, 429–430
 cervical cancer and, 460
 colorectal cancer and, 292
 endometrial cancer and, 483
 Hodgkin's lymphoma and, 662
 kidney cancer and, 607
 leukemias and, 704
 lung cancer and, 363
 nasopharyngeal carcinoma and, 186
 non-Hodgkin's lymphoma and, 679
 oropharyngeal cancer and, 168
 ovarian cancer and, 508
 pancreatic cancer and, 340
 prostate cancer and, 539
 skin cancer and, 389
 stomach cancer and, 262
 testicular cancer and, 562
 thyroid cancer and, 645
- Phytoestrogens
 breast cancer and, 413
 prostate cancer and, 529–530
- PIN (prostatic intraepithelial neoplasia), 517, 533
- Pleural mesothelioma, 8, 370–371
- Plummer-Vinson syndrome, 223–224
- Poison gas, occupational exposure to, 11
- Pollution. *See* Air pollution; Drinking water
 contamination; Environmental pollution
- Polyaromatic hydrocarbons, bladder cancer and, 586
- Polychlorinated biphenyls (PCBs)
 brain cancer and, 627
 breast cancer and, 434
 melanoma and, 389
 occupational exposure to, 10–11
- Polyclonal lineage, 64, 64f
- Polycyclic aromatic hydrocarbons (PAHS), lung
 cancer and, 365–366
- Polycystic ovarian syndrome, ovarian cancer and, 509
- Polygenic models of disease risk, gene–environment
 interaction and, 99–100
- Polymerase chain reaction (PCR), 100, 103
- Polymorphism databases, 95–96, 96t
- Polymorphisms. *See also* Single nucleotide
 polymorphisms; *specific polymorphisms*
 description of, 88, 103
 restriction fragment length polymorphism, 104
- Polyomavirus infection, bladder cancer and, 584
- Pooled analyses, 146
- Population stratification, 99
- Population studies, large-scale, 114
- Porphyria cutanea tarda, liver cancer and, 311
- Positional cloning, 90, 103–104
- Postmenopausal hormone use. *See* Hormone
 replacement therapy (HRT)
- Preeclampsia, 432
- Pregnancy. *See also* Prenatal exposures
 breast cancer and, 415–416
 non-Hodgkin's lymphoma and, 677
 thyroid cancer and, 644, 645
- Prenatal exposures
 breast cancer and, 23, 432
 to radiation, leukemias and, 706
 testicular cancer and, 564–566
- Prevalence, as measurement of disease burden, 35t,
 37, 38–41t, 42
- Progesterone, breast cancer and, 420
- Progesterone receptors
 endometrial cancer and, 473
 lung cancer and, 362
 ovarian cancer and, 498
- Progestin-only contraceptives, breast cancer and, 422
- Progestins, exogenous
 breast cancer and, 422, 425–426
 endometrial cancer and, 479–482, 480f, 481t, 482t
 as risk factor, 20–21
- Programmed cell death (apoptosis)
 in carcinogenesis, 74–76, 75f
 definition of, 102
 p53 protein and, 71–72
- Progression of cancer
 extrinsic factors and, 78–81, 80f
 stages of, 62–63
- Prolactin, breast cancer and, 420
- Prospective studies, 113, 134–135
- Prostaglandin pathway, colorectal cancer and, 283–
 284
- Prostate cancer, 517–542
 diagnosis, 518
 epidemiology
 descriptive, 518–521, 519f, 520f, 522f
 genetic and molecular, 521–525
 histologic subgroups, 517
 incidence, 56f, 57, 518–519, 519f, 520f, 522f
 inherited susceptibility, 521–523
 prognosis, 518
 research breakthrough in, 717–718
 risk factors
 age, 520f, 521
 alcohol consumption, 531
 anthropometric measures, 535–536
 diet, 526–531, 531t
 hormones, 532–535
 infections, 537–539
 ionizing radiation, 539
 medical conditions and treatment, 540–541
 occupational exposure, 539–540
 perinatal factors, 541
 physical activity, 539
 research on, 525–526, 535
 tobacco use, 526
 symptoms, 517
 treatment, 518
- Prostate specific antigen (PSA), 518, 519, 520–521
- Prostatic intraepithelial neoplasia (PIN), 517, 533
- Protein translation, suppression of, 69
- Proteomics, large-scale population studies and, 114

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Proto-oncogenes. *See also names of specific genes*
cell cycle regulators as, 70
description of, 66
PSA (prostate specific antigen), 518, 519, 520–521
Psoralen and ultraviolet A (PUVA), skin cancer and, 390
PTEN gene
breast cancer and, 406
endometrial cancer and, 473
Puberty. *See also* Menarche
testicular cancer and, 560–561
thyroid cancer and, 640, 645
Public health standards, causality determination and, 146
Publication bias, 121–123, 121f, 122f, 122t
Publicity of epidemiologic studies, 718
Pulmonary cancer. *See* Lung cancer
PUVA (psoralen and ultraviolet A), 390
p-value, 139–140, 151
- Quality-adjusted life year (QUALY). *See* Disability-adjusted life year
- Race
brain cancer and, 621
lung cancer and, 358
non-Hodgkin's lymphoma and, 670
skin cancer and, 379, 380
testicular cancer and, 559
Radiation. *See* Diagnostic radiation; Ionizing radiation; Radiotherapy; Ultraviolet radiation
Radiographs. *See* Diagnostic radiation
Radiotherapy
bladder cancer and, 585
brain cancer and, 625
leukemias and, 705f, 708–709
lung cancer and, 363, 366
ovarian cancer and, 509
skin cancer and, 389
stomach cancer and, 263
thyroid cancer and, 645, 646t
Radon exposure, lung cancer and, 363
Raloxifene, breast cancer and, 427
Random error, biomarker-based studies and, 120–121
Randomized controlled trials
definition of, 151
experimental design of, 130
limitations of, 141
Ras proto-oncogene, in carcinogenesis, 74
RAS proto-oncogene, thyroid cancer and, 642
Rate difference, 143
Rb gene
in carcinogenesis, 72
esophageal cancer and, 211, 212
Rb protein, in carcinogenesis, 72
RB1 gene
liver cancer and, 312
lung cancer and, 355–356
Recall bias, 142, 151
- Receptors
hormone. *See* Hormone receptors
steroid. *See* Steroid receptors
Recessive allele, 104
Rectal cancer. *See* Colorectal cancer
Reed-Sternberg cells, 653, 660, 660f, 661f
Relative risk, 135, 143–144, 151
Relative survival rate, 43
Renal cell neoplasms. *See* Kidney cancer
Renal disease, end stage, kidney cancer and, 608
Renal pelvis cancer, 573, 587, 597
Renal transplant, squamous cell carcinoma and, 389–390
Replication error phenotype, 93
Reproductive factors
biliary tract cancer and, 324–325
bladder cancer and, 584
brain cancer and, 624
breast cancer and, 17–18, 415–417
and cancer risk, 17–18
cervical cancer and, 451
colorectal cancer and, 291
endometrial cancer and, 18, 476–477
esophageal cancer and, 221
Hodgkin's lymphoma and, 659
kidney cancer and, 605
leukemias and, 702
liver cancer and, 316
lung cancer and, 362
nasopharyngeal carcinoma and, 184
non-Hodgkin's lymphoma and, 677
oropharyngeal cancer and, 167
ovarian cancer and, 18, 502–504
pancreatic cancer and, 338–339
skin cancer and, 387
testicular cancer and, 560–561
thyroid cancer and, 644
Residual confounding, 142
Respiratory diseases, chronic, lung cancer and, 366
Respiratory tract infections
brain cancer and, 628
nasopharyngeal carcinoma and, 186
Restriction fragment length polymorphism, 104
RET proto-oncogene, thyroid cancer and, 642
Retinoblastoma gene. *See* *Rb* gene
Retinoblastoma tumor pathways, 71, 72, 73f
Retinol. *See* Vitamin A
Retrospective cohort studies, 134–135
Rheumatoid arthritis, non-Hodgkin's lymphoma and, 682
Ribonuclease L, prostate cancer and, 524–525
Ribonucleic acid. *See* RNA
Richart classification of cervical cancer, 447
Risk difference, 143
Risk factors, 3–24. *See also under names of specific cancer sites*
alcohol consumption, 18–19
causal, accepted, 718t
cigarette smoking, 4–5
diet, 21–23
environmental exposure, 11–14
future research directions, 23–24

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Risk factors (*cont.*)
hypothesized, 718t
iatrogenic exposure, 19–20
ionizing radiation, 5–7
microorganisms, 14–17
occupational exposure, 7–11
reproductive factors, 17–18
RNA, description of, 104
RNA expression arrays, for large-scale population studies, 114
RNA interference (RNAi), 69
RNAi gene, prostate cancer and, 524–525
Rubber industry
bladder cancer and, 586
brain cancer and, 627–628
esophageal cancer risk and, 223
oral cancer risk and, 168
- Saccharin, bladder cancer and, 584
Salivary gland cancer, 155, 165, 167, 180
Salt intake
esophageal cancer and, 219
stomach cancer and, 257–258
Salt-preserved fish, nasopharyngeal carcinoma and, 183–184
Sample size requirements, 120–121
Sarcoma, myometrial, 468
Saturated fats, breast cancer and, 410–411
SCC. *See* Squamous cell carcinoma
Schistosoma haematobium infection, bladder cancer and, 573, 584, 590
Schistosoma japonicum infection, colorectal cancer and, 293
Sclerosing cholangitis
liver cancer and, 323
pancreatic cancer and, 343
Scrotal cancer, 555
Segregation, 104
Segregation analysis
in family pedigree analysis, 89
limitations of, 92–93
Selection bias, 116–117, 143, 151
Selective estrogen receptor modulators (SERMs), 339, 426–427, 484–485
Selenium
breast cancer and, 412
liver cancer and, 315
lung cancer and, 361
prostate cancer and, 530
skin cancer and, 387
Semen quality, testicular cancer and, 561, 566
Seminomas. *See* Testicular cancer
Senescence, 76–78
SERMs. *See* Selective estrogen receptor modulators
Serum hepatitis. *See* Hepatitis B virus infection; Hepatitis C virus infection
Sex hormones. *See names of specific hormone classes, e.g.,* Androgens
Sexual behavior
cervical cancer and, 446, 452, 455–459
human papilloma virus infection and, 455
prostate cancer and, 532, 537, 538
Sexually transmitted diseases
cervical cancer and, 446, 452–453
prostate cancer and, 537, 538
testicular cancer and, 562
Siblings, Hodgkin's lymphoma risk among, 658–659
Sibship size, Hodgkin's lymphoma and, 664–665
Signal transduction pathways, 71, 72, 74
Silent mutation, 104
Silica
esophageal cancer and, 220
lung cancer and, 365
stomach cancer and, 263
Simian virus 40
lung cancer and, 363
pleural mesothelioma and, 370
Single nucleotide polymorphisms (SNPs)
as biomarkers, 116, 138
databases of, 95–96, 96t
genotyping and, 100–101
tagging SNPs, linkage disequilibrium and, 95
Sjögren's syndrome, non-Hodgkin's lymphoma and, 682
Skin cancer, 378–394. *See also under* Basal cell carcinoma; Melanoma; Squamous cell carcinoma
diagnosis, 379
epidemiology
descriptive, 379–380, 380–382f
genetic and molecular, 380–385
histologic subgroups, 378
incidence, 55f, 57, 379–380, 380–382f
inherited susceptibility, 380–384
intermittent UV exposure theory, 391, 392–393
prognosis, 379
risk factors
alcohol consumption, 387
anthropometric measures, 388
diet, 386–387
hormones, 387–388
infections, 388–389
ionizing radiation, 5, 389
medical conditions and treatment, 389–390
occupational exposure, 389
physical activity, 389
reproductive factors, 387
tobacco use, 385–386
trauma, 394
ultraviolet radiation, 11–12, 390–394
somatic mutations, 384–385
symptoms, 378
treatment, 379
Slow acetylation polymorphism, and bladder cancer, 120–121, 121f
Small-cell carcinoma of lung
carcinogenesis of, 356f
histologic type distribution, 349
ionizing radiation and, 363
somatic mutations and, 355–356, 356t
tobacco use and, 358
Smoke, environmental exposure to
bladder cancer and, 582
leukemias and, 701

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Smoke, environmental exposure to (*cont.*)
 - lung cancer and, 338
 - nasopharyngeal carcinoma and, 183
 - as risk factor, 14
- Smokeless tobacco
 - bladder cancer and, 582
 - esophageal cancer and, 214, 215
 - kidney cancer and, 602
 - lung cancer and, 359
 - oral cancer and, 162–163
 - pancreatic cancer and, 337
- Smoking. *See* Tobacco use
- Smoking cessation
 - lung cancer and, 357
 - oral cancer and, 162
 - ovarian cancer and, 499
 - pancreatic cancer and, 337, 343
- smoothened* gene, skin cancer and, 382, 384
- SNPs. *See* Single nucleotide polymorphisms
- Snuff
 - bladder cancer and, 582
 - oral cancer and, 162–163
- Socioeconomic status
 - esophageal cancer and, 225
 - Hodgkin's lymphoma and, 664–665
 - kidney cancer and, 610
 - pancreatic cancer and, 340
 - stomach cancer and, 241, 265
 - testicular cancer and, 567
- Solar ultraviolet radiation, skin cancer and, 390–391
- Solvents, organic. *See* Organic solvents
- Somatic mutations. *See also under names of specific cancer sites*
 - definition of, 104
 - vs. germline mutations, 87
- Soyfoods
 - breast cancer and, 413
 - prostate cancer and, 529–530
 - stomach cancer and, 257
- Special exposure cohorts, 134
- Squamous cell carcinoma (SCC)
 - of bladder, 573, 584, 590
 - of cervix. *See* Cervical cancer
 - of esophagus. *See also* Esophageal cancer
 - alcohol consumption and, 213–215, 214f
 - diet and, 216
 - incidence, 196, 198–201
 - inherited susceptibility, 201–202
 - somatic mutations, 210–212
 - tobacco use and, 213–215, 214f
 - of larynx, 368
 - of lung
 - carcinogenesis of, 356f
 - chronic respiratory diseases and, 366
 - histologic type distribution, 349, 352
 - somatic mutations and, 355, 356t
 - tobacco use and, 358
 - of oropharynx. *See* Oral and pharyngeal cancer
 - of skin
 - alcohol consumption and, 387
 - anthropometric measures and, 388
 - diet and, 386–387
- Squamous cell carcinoma (SCC), of skin (*cont.*)
 - incidence, 379–380
 - infections and, 388
 - inherited susceptibility and, 383
 - medical conditions/treatment and, 389–390
 - somatic mutations and, 384
 - tobacco use and, 386
 - ultraviolet radiation and, 391
- Staging of tumors, 66
- Statin drugs, breast cancer and, 431–432
- Statistical analysis, 139–140
- Stem cells, carcinogenesis from, 65
- Steroid receptors. *See also* Hormone receptors
 - endometrial cancer and, 473–474, 474t
 - ovarian cancer and, 498
- Stomach cancer, 239–265
 - diagnosis, 240
 - epidemiology
 - descriptive, 240–245, 241–244f
 - genetic and molecular, 245–253
 - histologic subgroups, 239, 243–244
 - incidence, 50, 51f, 240–251, 241–243f
 - prognosis, 240
 - risk factors
 - alcohol consumption, 254
 - coffee consumption, 255
 - diet, 255–260, 266
 - infections, 16–17, 260–262, 261f, 265–266
 - ionizing radiation, 262–263
 - medical conditions and treatment, 264–265
 - occupational exposure, 263–264
 - physical activity, 262
 - socioeconomic status, 241, 265
 - tea consumption, 254–255
 - tobacco use, 253–254
 - symptoms, 239
 - treatment, 240
- Stop codon, 104
- Study base, 132–133, 151
- Study design, 129–139
 - analytic studies, 132
 - case-control studies, 135–138, 137f
 - cohort studies, 134–135, 136f
 - descriptive studies, 131
 - ecologic studies, 131–132
 - genetic epidemiology studies, 138–139
 - interventional studies, 129–130
 - observational studies, 130–131
 - person-time and, 132–134, 133f
 - study base and, 132–133
- Subfertility, testicular cancer and, 561, 566
- Sufficient cause, 128–129, 151
- Sulfate conjugation, esophageal cancer and, 205
- SULT1A1* gene, esophageal cancer and, 205
- Sunlamps, skin cancer and, 394
- Survival, period analysis of, 43
- Survival rate
 - corrected, 42–43
 - as measurement of disease burden, 35t, 42–43
 - observed, 42
 - overall, 57–58, 58t
 - relative, 43

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Survivor bias, 99
Susceptibility biomarkers, 111, 112t, 116
Sweeteners, artificial
 bladder cancer and, 584
 kidney cancer and, 604
Syphilis
 oral cancer and, 168
 prostate cancer and, 537
Systematic errors, 140–143, 142f, 143f. *See also* Bias;
 Confounding
- T lymphocytes
 in apoptosis, 75–76
 in immune-mediated tumor eradication, 80–81,
 80f
Tagging SNPs, 95
Talcum powder, ovarian cancer and, 509–510
Tamoxifen
 breast cancer and, 426–427
 endometrial cancer and, 484–485
 pancreatic cancer and, 339
Tar content of cigarettes, lung cancer and, 357–358
Tea consumption. *See also* Green tea
 bladder cancer and, 583
 kidney cancer and, 604
 lung cancer and, 359
 ovarian cancer and, 501
 stomach cancer and, 254–255
 thyroid cancer and, 644
Telomerase, 77–78
Telomerase transcriptase gene (hTERT), stomach
 cancer and, 253
Telomeres, 77–78, 77f
Testicular cancer, 555–567
 diagnosis, 556
 epidemiology
 descriptive, 556–559, 556–558f
 genetic and molecular, 559
 histologic subgroups, 555
 incidence, 555, 556–559, 556–558f
 inherited susceptibility, 559
 prognosis, 556
 risk factors, 560t, 567
 alcohol consumption, 560
 anthropometric measures, 561–562
 diet, 560
 infections, 562
 ionizing radiation, 562
 medical conditions and treatment, 563–564
 occupational exposure, 562–563
 physical activity, 562
 prenatal exposures, 564–566
 reproductive factors and hormones, 560–561,
 565
 semen quality and fertility, 561
 socioeconomic status, 567
 tobacco use, 560
 trauma, 566
 vasectomy, 567
 somatic mutations, 559
 symptoms, 555–556
 treatment, 556
 Testicular dysgenesis syndrome, 566
 Testicular germ cell tumor cell 1, 559
 Testosterone
 liver cancer and, 316–317
 prostate cancer and, 532–533
Tetrachloroethylene. *See* Chlorinated hydrocarbon
 solvents
TGF- α . *See* Transforming growth factor- α
Thermal injury, skin cancer and, 394
Thorotrast
 kidney cancer and, 607
 liver cancer and, 6–7, 322, 325
 pleural mesothelioma and, 370
Thymidylate synthase, esophageal cancer and, 206,
 207
Thyroid cancer, 636–649
 breast cancer and, 648
 diagnosis, 637
 epidemiology
 descriptive, 637–640, 638t, 639f, 640f, 640t,
 641f
 genetic and molecular, 640–643, 648
 histologic subgroups, 636, 638t
 incidence, 637–640, 638t, 639f, 640f, 640t, 641f,
 648
 inherited susceptibility, 640–641, 642t
 prognosis, 637
 risk factors
 alcohol consumption, 644
 anthropometric measures, 645
 diet, 643–644
 hormones, 644–645
 ionizing radiation, 6, 645–647, 645t, 646t,
 648–649
 medical conditions and treatment, 647–648
 occupational exposure, 647
 physical activity, 645
 reproductive factors, 644
 tobacco use, 643
 somatic mutations, 641–643
 symptoms, 636
 treatment, 637
Thyroid disease
 breast cancer and, 431
 thyroid cancer and, 647–648
Thyroid stimulating hormone (TSH)
 elevated levels of, and thyroid cancer, 644–645,
 649
 tobacco use and, 643
Tire industry. *See* Rubber industry
TLR4 gene, stomach cancer and, 247–248
T/NK-cell neoplasia, 669–670, 671t. *See also* Non-
 Hodgkin's lymphoma
Tobacco use
 bladder cancer and, 578–579, 578f, 580–582,
 581t, 590
 brain cancer and, 622–623
 breast cancer and, 408
 cervical cancer and, 450
 colorectal cancer and, 284–285
 confounding effect of, 358
 endometrial cancer and, 474–475

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Tobacco use (*cont.*)
 esophageal cancer and, 202–203, 213–216
 Hodgkin's lymphoma and, 659
 interactions with other carcinogens, 358–359
 kidney cancer, 602–603, 603t
 laryngeal cancer and, 368
 leukemias and, 701
 liver cancer and, 314
 lung cancer and, 4–5, 357–359
 nasopharyngeal carcinoma and, 182–183
 non-Hodgkin's lymphoma and, 675–676
 oropharyngeal cancer and, 162–164, 166f
 ovarian cancer and, 499
 pancreatic cancer and, 336–337
 prostate cancer and, 526
 skin cancer and, 385–386
 stomach cancer and, 253–254
 testicular cancer and, 560, 564
 thyroid cancer and, 643
- Toll-like receptors
 prostate cancer and, 525
 stomach cancer and, 247–248
- Tomatoes
 pancreatic cancer and, 337
 prostate cancer and, 528–529
- Tonsillectomy, Hodgkin's lymphoma and, 664
- Total energy intake
 kidney cancer and, 604
 stomach cancer and, 259
- Toxoplasma gondii* infection, brain cancer and, 624
- TP53* gene. *See also p53* gene
 bladder cancer and, 580
 Li-Fraumeni syndrome and, 93
 liver cancer and, 312, 315, 318
 lung cancer and, 355
 stomach cancer and, 246, 252
- Trace elements. *See also* Micronutrients
 esophageal cancer and, 217
 nasopharyngeal carcinoma and, 187–188
 stomach cancer and, 259
- Transcription, 104
- Transforming growth factor- α (TGF- α)
 esophageal cancer and, 213
 liver cancer and, 312
 stomach cancer and, 251–252
- Transitional cell carcinoma. *See* Bladder cancer
- Transitional studies, 118–119, 118t
- Translation, 104
- Translocation, 104
- Transmission disequilibrium test, 98
- Transplants. *See* Organ transplants
- Trauma
 brain cancer and, 628–629
 skin cancer and, 394
 testicular cancer and, 566
- Trichloroethylene. *See* Chlorinated hydrocarbon solvents
- Trichomonas vaginalis* infection, prostate cancer and, 538
- TS* gene, esophageal cancer and, 207, 208
- TSH. *See* Thyroid stimulating hormone
- Tubal ligation, ovarian cancer and, 503–504
- Tuberculosis
 brain cancer and, 624
 lung cancer and, 362, 366
- Tumors. *See also* Cancer
 benign vs. malignant, 62, 62t
 grading and staging of, 66
- Tumor-suppressor genes. *See also names of specific genes*
 cell cycle regulators as, 70
 description of, 66
 liver cancer and, 312
 ovarian cancer and, 498–499
- Twin births
 breast cancer and, 432
 Hodgkin's lymphoma risk and, 658–659
 leukemia risk and, 699
- Twin pregnancy, testicular cancer and, 565
- Two-hit theory of carcinogenesis, 67–68, 67f, 280
- Tylosis, esophageal cancer and, 201–202
- Ulcer, gastric, stomach cancer and, 264
- Ultraviolet radiation
 non-Hodgkin's lymphoma and, 684–685
 skin cancer and, 11–12, 390–394
- United States, cancer mortality trends in, 48–49, 49–50f
- Ureters, cancer of, 573
- Urinary bladder cancer. *See* Bladder cancer
- Urinary tract infections
 bladder cancer and, 584
 kidney cancer and, 609
- Urine pH, bladder cancer and, 589
- Urolithiasis
 bladder cancer and, 587
 kidney cancer and, 609
- Uterine cancer. *See* Cervical cancer; Endometrial cancer
- Uterine papillary serous carcinoma, 469
- Vaccination
 for hepatitis B virus infection, 15
 for human papilloma virus infection, 460
 leukemias and, 709
 non-Hodgkin's lymphoma and, 683
- Vaginal adenocarcinoma, diethylstilbesterol and, 19–20
- Variant, definition of, 104
- Variation, in biomarker-based studies, 117–118, 117t
- Varicella-zoster infection, brain cancer and, 624
- Vasectomy
 prostate cancer and, 540–541
 testicular cancer and, 567
- Vegetable consumption
 bladder cancer and, 582–583
 brain cancer and, 623
 breast cancer and, 413–414
 cervical cancer and, 451
 colorectal cancer and, 285–288
 endometrial cancer and, 476
 esophageal cancer and, 216, 218, 220, 221
 kidney cancer and, 603
 laryngeal cancer and, 368

Index for *Textbook of Cancer Epidemiology, 2nd ed.*, Adami et al.
Oxford University Press, 2008

- Vegetable consumption (*cont.*)
 liver cancer and, 315
 lung cancer and, 359
 nasopharyngeal carcinoma and, 184
 oral cancer and, 164
 ovarian cancer and, 501
 pancreatic cancer and, 337
 stomach cancer and, 255
 thyroid cancer and, 643
VHL tumor suppressor gene, kidney cancer and, 601, 602
Vinyl chloride
 brain cancer and, 626
 liver cancer and, 322–323
 occupational exposure to, 11
Viral infections. *See also names of specific viral infections*
 in cancer etiology, 66–67
Vitamin A (retinol)
 breast cancer and, 411–412
 liver cancer and, 315
 stomach cancer and, 256–257
Vitamin C (ascorbic acid)
 breast cancer and, 412
 cervical cancer and, 451
 oral cancer and, 165
 pancreatic cancer and, 337
 stomach cancer and, 255–256
Vitamin D
 breast cancer and, 413
 colorectal cancer and, 290
 non-Hodgkin's lymphoma and, 684–685
 prostate cancer and, 528
Vitamin D receptor, prostate cancer and, 524
Vitamin E (alpha-tocopherol)
 breast cancer and, 412
 cervical cancer and, 451
 oral cancer and, 165
 prostate cancer and, 530–531
 stomach cancer and, 256
Vitamins
 bladder cancer and, 582
 colorectal cancer and, 287–288
 esophageal cancer and, 216–218
 lung cancer and, 360
Voiding frequency, bladder cancer and, 589
von Hippel-Lindau syndrome, kidney cancer and, 600–601
Water pollution. *See* Drinking water contamination
Weight. *See* Body mass index; Obesity
Weight change
 breast cancer and, 428
 kidney cancer and, 605
 prostate cancer and, 536
Werner's syndrome
 genetic mutations in, 70–71
 melanoma and, 384
 thyroid cancer and, 641
WHO. *See* World Health Organization
Whole genome scans, 101, 116
Women, cancer incidence in
 age-standardized incidence, 38t, 51–56f
 bladder cancer, 574, 575f, 576f
 brain cancer, 620, 620f, 621f
 breast cancer, 404–405, 405f, 406f
 cervical cancer, 447–449, 448f, 449f
 colorectal cancer, 276, 277f, 278f
 cumulative incidence, 40t
 endometrial cancer, 469–470, 470f, 471f
 esophageal cancer, 197–198, 197f, 199f
 Hodgkin's lymphoma, 654, 654f, 655f, 656, 657f
 kidney cancer, 598, 599f, 600f
 laryngeal cancer, 368f, 369f
 leukemia, 696, 697f, 698f
 liver cancer, 309f, 310, 310f
 lung cancer, 350, 351f, 352f, 358
 melanoma, 380, 380f, 381f
 nasopharyngeal carcinoma, 177, 178f, 179f
 non-Hodgkin's lymphoma, 670, 672f, 673f
 oropharyngeal cancer, 156–158, 156f, 157f
 ovarian cancer, 495–496, 495f, 496f
 pancreatic cancer, 334f, 335f, 336
 by site, 46f
 stomach cancer, 240–241, 241f, 242f
 thyroid cancer, 637, 639–640, 639f, 640f, 640t
Wood dust, occupational exposure to, 11, 186–187
Woodworking industry, Hodgkin's lymphoma and, 662
World Health Organization (WHO)
 cervical dysplasia classification system, 447
 classification of endometrial cancers, 468
 lymphoma classification, 669–670, 671t
X-chromosome inactivation, 64–65
Xenoestrogens, environmental, endometrial cancer and, 484
Xeroderma pigmentosum
 esophageal cancer and, 207–208
 skin cancer and, 382–383
X-linkage, 104
XMRV virus, prostate cancer and, 538–539
XPC gene, esophageal cancer and, 207–208
XPD gene, esophageal cancer and, 207–208
XPG gene, esophageal cancer and, 208
X-rays, diagnostic. *See* Diagnostic radiation
Y-chromosome abnormalities, testicular cancer and, 559
Y-chromosome loss, esophageal adenocarcinoma and, 213
Years of life lost, as measurement of disease burden, 35t, 44